|
Document and Entity Information
|
12 Months Ended |
|---|---|
|
Dec. 31, 2011
|
|
| Document Information [Line Items] | |
| Document Type | 20-F |
| Amendment Flag | false |
| Document Period End Date | Dec. 31, 2011 |
| Document Fiscal Year Focus | 2011 |
| Document Fiscal Period Focus | FY |
| Trading Symbol | ICLR |
| Entity Registrant Name | ICON PLC /ADR/ |
| Entity Central Index Key | 0001060955 |
| Current Fiscal Year End Date | --12-31 |
| Entity Well-known Seasoned Issuer | Yes |
| Entity Current Reporting Status | Yes |
| Entity Filer Category | Large Accelerated Filer |
| Entity Common Stock, Shares Outstanding | 60,135,603 |
| X | ||||||||||
|
- Definition
If the value is true, then the document as an amendment to previously-filed/accepted document. No definition available.
|
| X | ||||||||||
|
- Definition
End date of current fiscal year in the format --MM-DD. No definition available.
|
| X | ||||||||||
|
- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No definition available.
|
| X | ||||||||||
|
- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD. No definition available.
|
| X | ||||||||||
|
- Definition
The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other. No definition available.
|
| X | ||||||||||
|
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument No definition available.
|
| X | ||||||||||
|
- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. No definition available.
|
| X | ||||||||||
|
- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. No definition available.
|
| X | ||||||||||
|
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. No definition available.
|
| X | ||||||||||
|
- Definition
Trading symbol of an instrument as listed on an exchange. No definition available.
|
| X | ||||||||||
|
- Definition
Noncurrent capital government grants, which are amortized and recognized in earnings over the grant period. No definition available.
|
| X | ||||||||||
|
- Definition
Capital Redemption Reserve No definition available.
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature within one year from the balance sheet date or the normal operating cycle, whichever is longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference. An unrecognized tax benefit that is directly related to a position taken in a tax year that results in a net operating loss carryforward is presented as a reduction of the related deferred tax asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The noncurrent portion as of the balance sheet date of the aggregate carrying amount of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after the valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, is classified according to the expected reversal date of the temporary difference. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Represents the current portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A current taxable temporary difference is a difference between the tax basis and the carrying amount of a current asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise separates deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, is classified according to the expected reversal date of the temporary difference. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise separates deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate sum of gross carrying value of a major finite-lived intangible asset class, less accumulated amortization and any impairment charges. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount due after one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
CONSOLIDATED BALANCE SHEETS (Parenthetical) (EUR €)
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Ordinary shares, par value | € 0.06 | € 0.06 |
| Ordinary shares, shares authorized | 100,000,000 | 100,000,000 |
| Ordinary shares, shares issued | 60,135,603 | 60,247,092 |
| Ordinary shares, shares outstanding | 60,135,603 | 60,247,092 |
| X | ||||||||||
|
- Definition
Face amount or stated value of common stock per share; generally not indicative of the fair market value per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Revenue: | |||
| Gross revenue | $ 1,296,509 | $ 1,263,147 | $ 1,258,227 |
| Reimbursable expenses | (350,780) | (363,103) | (370,615) |
| Net revenue | 945,729 | 900,044 | 887,612 |
| Costs and expenses: | |||
| Direct costs | 611,923 | 541,388 | 507,783 |
| Selling, general and administrative | 255,864 | 232,688 | 230,910 |
| Depreciation and amortization | 38,682 | 33,873 | 32,659 |
| Non -recurring charges, net (Note 14) | 9,817 | 8,808 | |
| Total costs and expenses | 916,286 | 807,949 | 780,160 |
| Income from operations | 29,443 | 92,095 | 107,452 |
| Interest Income | 1,194 | 1,761 | 752 |
| Interest expense | (1,642) | (1,132) | (3,530) |
| Income before provision for income taxes | 28,995 | 92,724 | 104,674 |
| Provision for income taxes (Note 13) | (6,115) | (5,653) | (10,375) |
| Net income | $ 22,880 | $ 87,071 | $ 94,299 |
| Net income per ordinary share: | |||
| Basic | $ 0.38 | $ 1.46 | $ 1.61 |
| Diluted | $ 0.37 | $ 1.44 | $ 1.57 |
| Weighted average number of ordinary shares outstanding: | |||
| Basic (Note 2) | 60,379,338 | 59,718,934 | 58,636,878 |
| Diluted (Note 2) | 61,070,686 | 60,637,103 | 59,900,504 |
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations net of research and development incentives. No definition available.
|
| X | ||||||||||
|
- Definition
Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Cost associated with reimbursable income. This occurs when a services entity incurs expenses on behalf of the client and passes through the cost of reimbursable expenses to a client. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Total costs of sales and operating expenses for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Long Term Funding Tax No definition available.
|
| X | ||||||||||
|
- Definition
Adjustment that results from the process of translating the impact of long-term funding into the functional currency of the reporting entity, net of tax No definition available.
|
| X | ||||||||||
|
- Definition
This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation". Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Direct costs (e.g., legal and accounting fees) associated with issuing stock that is deducted from additional paid in capital. Also includes any direct costs associated with stock issues under a shelf registration. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tax benefit associated with any equity-based compensation plan other than an employee stock ownership plan (ESOP). The tax benefit results from the deduction by the entity on its tax return for an award of stock that exceeds the cumulative compensation cost for common stock or preferred stock recognized for financial reporting. Includes any resulting tax benefit that exceeds the previously recognized deferred tax asset (excess tax benefits). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The adjustment out of other comprehensive income for the net transition asset or obligation recognized as a component of net periodic benefit cost during the period, after tax. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Appreciation or loss in value (before reclassification adjustment) of the total of unsold securities during the period being reported on, net of tax. Reclassification adjustments include: (1) the unrealized holding gain (loss), net of tax, at the date of the transfer for a debt security from the held-to-maturity category transferred into the available-for-sale category. Also includes the unrealized gain (loss) at the date of transfer for a debt security from the available-for-sale category transferred into the held-to-maturity category; (2) the unrealized gains (losses) realized upon the sale of securities, after tax; and (3) the unrealized gains (losses) realized upon the write-down of securities, after tax. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value stock issued during the period as a result of the exercise of stock options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares that have been repurchased and retired during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Increase (Decrease) In Prepaid Expense And Other Current Assets No definition available.
|
| X | ||||||||||
|
- Definition
Payments for Share Repurchase Costs No definition available.
|
| X | ||||||||||
|
- Definition
Proceeds From Government Grant No definition available.
|
| X | ||||||||||
|
- Definition
Amortization of Government Grants. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The effect of exchange rate changes on cash balances held in foreign currencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Reductions in the entity's income taxes that arise when compensation cost (from non-qualified share-based compensation) recognized on the entity's tax return exceeds compensation cost from equity-based compensation recognized in financial statements. This element represents the cash inflow reported in the enterprise's financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows. No definition available.
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net cash inflow or outflow from financing activity for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net cash inflow or outflow from investing activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow to reacquire common stock during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow for cost incurred directly with the issuance of an equity security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cash outflow to pay off an obligation from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Description of business
|
12 Months Ended |
|---|---|
|
Dec. 31, 2011
|
|
| Description of business |
1. Description of business
ICON
plc and its subsidiaries (“the Company” or
“ICON”) is a contract research organization
(“CRO”), providing outsourced development services on a
global basis to the pharmaceutical, biotechnology and medical
device industries. The Company specializes in the strategic
development, management and analysis of programs that support
Clinical Development - from compound selection to Phase I-IV
clinical studies.
In
a highly fragmented industry, we are one of a select group of
companies with the capability and expertise to conduct clinical
trials in all major therapeutic areas on a global basis. At
December 31, 2011 the Company had 8,470 employees, in 81 locations,
in 40 countries, providing Phase I - IV Clinical Trial Management,
Drug Development Support Services, Data Management, Biostatistics,
Central Laboratory, Imaging and Staff Contracting services. The
Company has the operational flexibility to provide development
services on a stand-alone basis or as part of an integrated
“full service” solution.
Headquartered
in Dublin, Ireland, we began operations in 1990 and have expanded
our business through internal growth and strategic acquisitions.
For the year ended December 31, 2011 we derived approximately
41.7%, 46.2 % and 12.1 % of our net revenue in the United States,
Europe and Rest of World, respectively.
|
| X | ||||||||||
|
- Definition
The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Significant Accounting Policies
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Significant Accounting Policies |
2. Significant Accounting Policies
The
accounting policies noted below were applied in the preparation of
the accompanying financial statements of the Company and are in
conformity with accounting principles generally accepted in the
United States.
(a) Basis
of consolidation
The
consolidated financial statements include the financial statements
of the Company and all of its subsidiaries. All significant
intercompany profits, transactions and account balances have been
eliminated. The results of subsidiary undertakings acquired in the
period are included in the consolidated statement of operations
from the date of acquisition.
(b) Use
of estimates
The
preparation of financial statements in conformity with generally
accepted accounting principles in the United States requires
management to make estimates and judgments that affect the reported
amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reported
period. Actual results could differ from those estimates. The
principle management estimates and judgements used in preparing the
financial statements relate to revenue recognition, taxation,
goodwill and business combinations.
(c) Revenue
recognition
The
Company primarily earns revenues by providing a number of different
services to its customers. These services, which are integral
elements of the clinical development process, include clinical
trials management, biometric activities, consulting, imaging,
contract staffing, informatics and laboratory services. Contracts
range in duration from a number of months to several
years. Revenue for services, as rendered, is recognized
only after persuasive evidence of an arrangement exists, the sales
price is fixed or determinable and collectability is reasonably
assured.
Clinical
trials management revenue is recognized on a proportional
performance method. Depending on the contractual terms revenue is
either recognized on the percentage of completion method based on
the relationship between hours incurred and the total estimated
hours of the trial or on the unit of delivery method. Contract
costs equate to the product of labor hours incurred and
compensation rates. For the percentage of completion
method, the input (effort expended) method has been used to measure
progress towards completion as there is a direct relationship
between input and productivity. Contract revenue is the product of
the aggregated labor hours required to complete the specified
contract tasks at the agreed contract rates. The Company regularly
reviews the estimate of total contract time to ensure such
estimates remain appropriate taking into account actual contract
stage of completion, remaining time to complete and any identified
changes to the contract scope. Remaining time to complete depends
on the specific contract tasks and the complexity of the contract
and can include geographical site selection and initiation, patient
enrolment, patient testing and level of results analysis required.
While the Company may routinely adjust time estimates, the
Company’s estimates and assumptions historically have been
accurate in all material respects in the
aggregate. Where revenue is recognized on the unit of
delivery method, the basis applied is the number of units completed
as a percentage of the total number of contractual
units.
Biometrics
revenue is recognised on a fee-for-service method as each unit of
data is prepared on the basis of the number of units completed in a
period as a percentage of the total number of contracted
units. Imaging revenue is recognised on a
fee-for-service basis recognizing revenue for each image completed.
Consulting revenue is recognised on a fee-for-service basis as each
hour of the related service is performed. Contract staffing
revenue is recognized on a fee-for-service basis, over the time the
related service is performed, or in the case of permanent
placement, once the candidate has been placed with the
client. Informatics revenue is recognized on a
fee-for-service basis. Informatics contracts are
treated as multiple element arrangements, with contractual elements
comprising licence fee revenue, support fee revenue and revenue
from software services, each of which can be sold separately. Sales
prices for contractual elements are determined by reference to
objective and reliable evidence of their sales price. Licence and
support fee revenues are recognized rateably over the period of the
related agreement. Revenue from software services is
recognized using the percentage of completion method based on the
relationship between hours incurred and the total estimated hours
required to perform the service.
Laboratory
service revenue is recognised on a fee-for-service basis. The
Company accounts for laboratory service contracts as multiple
element arrangements, with contractual elements comprising
laboratory kits and laboratory testing, each of which can be sold
separately. Sales prices for contractual elements are determined by
reference to objective and reliable evidence of their sales price.
Revenues for contractual elements are recognised on the basis of
the number of deliverable units completed in the
period.
Contracts
generally contain provisions for renegotiation in the event of
changes in the scope, nature, duration, or volume of services of
the contract. Renegotiated amounts are recognised as revenue by
revision to the total contract value arising as a result of an
authorised customer change order.
The
difference between the amount of revenue recognised and the amount
billed on a particular contract is included in the balance sheet as
unbilled revenue or payments on account. Normally, amounts become
billable upon the achievement of certain milestones, for example,
target patient enrollment rates, clinical testing sites initiated
or case report forms completed. Once the milestone target is
reached, amounts become billable in accordance with pre-agreed
payment schedules included in the contract or on submission of
appropriate billing detail. Such cash payments are not
representative of revenue earned on the contract as revenues are
recognised over the period in which the specified contractual
obligations are fulfilled. Amounts included in unbilled revenue are
expected to be collected within one year and are included within
current assets. Advance billings to customers, for which revenue
has not been recognised, are recognised as payments on account
within current liabilities.
In
the event of contract termination, if the value of work performed
and recognised as revenue is greater than aggregate milestone
billings at the date of termination, cancellation clauses ensure
that the Company is paid for all work performed to the termination
date.
(d) Reimbursable
expenses
Reimbursable
expenses comprise investigator payments and certain other costs
which are reimbursed by clients under terms specific to each
contract and are deducted from gross revenue in arriving at net
revenue. Investigator payments are accrued based on patient
enrollment over the life of the contract. Investigator payments are
made based on predetermined contractual arrangements, which may
differ from the accrual of the expense. Payments to investigators
in excess of the accrued expense are classified as prepaid expenses
and accrued expense in excess of amounts paid are classified as
accounts payable.
(e) Direct
costs
Direct
costs consist of compensation, associated employee benefits and
share-based payments for project-related employees and other direct
project-related costs.
(f) Advertising
costs
All
costs associated with advertising and promotion are expensed as
incurred. The advertising and promotion expense was $2,905,000,
$3,431,000 and $2,548,000 for the years ended December 31, 2011,
December 31, 2010 and December 31, 2009 respectively.
(g) Foreign
currencies and translation of subsidiaries
The
Company's financial statements are prepared in United States
dollars. Transactions in currencies other than United States
dollars are recorded at the rate ruling at the date of the
transactions. Monetary assets and liabilities denominated in
currencies other than United States dollars are translated into
United States dollars at exchange rates prevailing at the balance
sheet date. Adjustments resulting from these translations are
charged or credited to income. Amounts credited or
charged to the statement of operations for the years ended December
31, 2011, December 31, 2010 and December 31, 2009 were as
follows:
The
financial statements of subsidiaries with other functional
currencies are translated at period end rates for the balance sheet
and average rates for the statement of operations. Translation
gains and losses arising are reported as a movement on accumulated
other comprehensive income.
(h) Disclosure
about fair value of financial instruments
The
following methods and assumptions were used to estimate the fair
value of each material class of financial instrument:
Cash,
cash equivalents, unbilled revenue, other receivables, short term
investments, prepayments and other current assets, accounts
receivable, accounts payable, investigator payments, payments
received on account, accrued liabilities, accrued bonuses, bank
overdraft and taxes payable have carrying amounts that approximate
fair value due to the short term maturities of these instruments.
Other liabilities’ carrying amounts approximate fair value
based on net present value of estimated future cash
flows.
(i) Business
combinations
The
cost of a business combination is measured as the aggregate of the
fair values at the date of exchange of assets given, liabilities
incurred or assumed and equity instruments issued in exchange for
control. Where a business combination agreement provides for an
adjustment to the cost of the acquisition which is contingent upon
future events, the amount of the estimated adjustment is recognised
on the acquisition date at the acquisition date fair value of this
contingent consideration. Any changes to this estimate in
subsequent periods will depend on the classification of the
contingent consideration. If the contingent consideration is
classified as equity it shall not be re-measured and the settlement
shall be accounted for within equity. If the contingent
consideration is classified as an asset or liability any
adjustments will be accounted for through the Consolidated
Statement of Operations or other comprehensive income depending on
whether the asset or liability is considered a financial
instrument.
The
assets, liabilities and contingent liabilities of businesses
acquired are measured at their fair values at the date of
acquisition. In the case of a business combination which is
completed in stages, the fair values of the identifiable assets,
liabilities and contingent liabilities are determined at the date
of each exchange transaction. When the initial accounting for a
business combination is determined provisionally, any subsequent
adjustments to the provisional values allocated to the identifiable
assets, liabilities and contingent liabilities are made within
twelve months of the acquisition date and presented as adjustments
to the original acquisition accounting.
(j) Goodwill
and Impairment
Goodwill
represents the excess of the cost of acquired entities over the net
amounts assigned to assets acquired and liabilities assumed.
Goodwill primarily comprises acquired workforce in place which does
not qualify for recognition as an asset apart from
goodwill. Goodwill is stated net of any provision for
impairment. The Company tests goodwill annually for any impairments
or whenever events occur which may indicate impairment. The first
step is to compare the carrying amount of the reporting
unit’s assets to the fair value of the reporting unit. If the
carrying amount exceeds the fair value then a second step is
completed which involves the fair value of the reporting unit being
allocated to each asset and liability with the excess being implied
goodwill. The impairment loss is the amount by which the recorded
goodwill exceeds the implied goodwill. No impairment was recognized
as a result of the impairment testing carried out for the years
ended December 31, 2011, December 31, 2010 and December 31,
2009.
(k) Intangible
assets
Intangible
assets are amortized on a straight line basis over their estimated
useful life.
(l) Cash
and cash equivalents
Cash
and cash equivalents include cash and highly liquid investments
with initial maturities of three months or less and are stated at
cost, which approximates market value.
(m) Short
term investments - available for sale
The
Company classifies short-term investments as available for sale in
accordance with the terms of FASB ASC 320, Investments – Debt and
Equity Securities. Realized gains and losses are
determined using specific identification. The
investments are reported at fair value, with unrealized gains or
losses reported in a separate component of shareholders’
equity. Any differences between the cost and fair value
of the investments are represented by accrued
interest.
(n) Inventory
Inventory
is valued at the lower of cost and net market value and after
provisions for obsolescence. Cost of raw materials comprises the
purchase price and attributable costs, less trade
discounts. At December 31, 2011 the carrying value of
inventory, included within prepayments and other current assets on
the balance sheet, was $2.8 million (2010: $3.8
million).
(o) Property,
plant and equipment
Property,
plant and equipment is stated at cost less accumulated
depreciation. Depreciation of property, plant and equipment is
computed using the straight line method based on the estimated
useful lives of the assets as listed below:
Leasehold
improvements are amortized using the straight-line method over the
estimated useful life of the asset or the lease term, whichever is
shorter.
(p) Leased
assets
Costs
in respect of operating leases are charged to the statement of
operations on a straight line basis over the lease
term.
Assets
acquired under capital finance leases are included in the balance
sheet at the present value of the future minimum lease payments and
are depreciated over the shorter of the lease term and their
remaining useful lives. The corresponding liabilities are recorded
in the balance sheet and the interest element of the capital lease
rental is charged to interest expense.
(q) Income
taxes
The
Company applies FASB ASC 740, Income Taxes
(“ASC 740”), which requires the asset and liability
method of accounting for income taxes. Under the asset and
liability method of ASC 740, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to
differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases, and
operating loss and tax credit carryforwards. Deferred tax assets
and liabilities are measured using enacted tax rates expected to
apply to taxable income in the years in which these temporary
differences are expected to be recovered or settled. The effect on
deferred tax assets and liabilities of a change in tax rates is
recognized in income in the period that includes the enactment
date. ASC 740 requires that the Company recognizes the
largest amount of tax benefit that is greater than 50% likely of
being realized upon effective settlement when considering uncertain
tax positions.
(r) Government
grants
Government
grants received relating to capital expenditure are shown as
deferred income and credited to income on a basis consistent with
the depreciation policy of the relevant assets. Grants
relating to categories of operating expenditures are credited to
income in the period in which the expenditure to which they relate
is charged.
Under
the grant agreements amounts received may become repayable in full
should certain circumstances specified within the grant agreements
occur, including downsizing by the Company, disposing of the
related assets, ceasing to carry on its business or the appointment
of a receiver over any of its assets. The Company has
not recognized any loss contingency having assessed as remote the
likelihood of these events arising.
(s) Research
and development credits
Research
and development credits are available to the Company under the tax
laws in certain jurisdictions, based on qualifying research and
development spend as defined under those tax laws. Research and
development credits are generally recognized as a reduction of
income tax expense. However, certain tax jurisdictions provide
refundable credits that are not wholly dependent on the
Company’s ongoing income tax status or income tax position.
In these circumstances the benefit of these credits is not recorded
as a reduction to income tax expense, but rather as a reduction of
the operating expenditure to which the credits relate.
(t) Pension
costs
The
Company contributes to defined contribution plans covering all
eligible employees. The Company contributes to these plans based
upon various fixed percentages of employee compensation and such
contributions are expensed as incurred.
The
Company operates, through a subsidiary, a defined benefit plan for
certain of its United Kingdom employees. The Company accounts for
the costs of this plan using actuarial models required by FASB ASC
715-30 and the plan is presented in accordance with the
requirements of FASB ASC 715-60 Defined Benefit Plans –
Other Postretirement.
(u) Net
income per ordinary share
Basic
net income per ordinary share has been computed by dividing net
income available to ordinary shareholders by the weighted average
number of ordinary shares outstanding during the period. Diluted
net income per ordinary share is computed by adjusting the weighted
average number of ordinary shares outstanding during the period for
all potentially dilutive ordinary shares outstanding during the
period and adjusting net income for any changes in income or loss
that would result from the conversion of such potential ordinary
shares.
There
is no difference in net income used for basic and diluted net
income per ordinary share. The reconciliation of the number of
shares used in the computation of basic and diluted net income per
ordinary share is as follows:
(v) Share-based
compensation
The
Company accounts for its share options in accordance with the
provisions of FASB ASC 718, Compensation – Stock
Compensation. Share-based compensation expense for
equity-settled awards made to employees and directors is measured
and recognized based on estimated grant date fair values. These
awards include employee stock options.
Share-based
compensation expense for stock options awarded to employees and
directors is estimated at the grant date based on each
option’s fair value as calculated using the Black-Scholes
option-pricing model. The value of awards expected to vest is
recognized as an expense over the requisite service
periods.
Estimating
the fair value of share-based awards as of the grant date using an
option-pricing model, such as the Black-Scholes model, is affected
by the Company’s share price as well as assumptions regarding
a number of complex variables. These variables include, but are not
limited to, the expected share price volatility over the term of
the awards, risk-free interest rates, and the expected term of the
awards.
(w) Impairment
of long-lived assets
Long
lived assets are reviewed for impairment whenever events or changes
in circumstances indicate that the carrying amount of an asset may
not be recoverable. Recoverability of assets to be held and used is
measured by a comparison of the carrying amount of an asset to
future undiscounted net cash flows expected to be generated by the
asset. If such assets are considered to be impaired, the impairment
to be recognized is measured by the amount by which the carrying
amount of the assets exceeds the fair value of the assets. Assets
to be disposed of are reported at the lower of the carrying amount
or fair value less selling costs.
(x) Reclassifications
Certain
amounts in the consolidated financial statements have been
reclassified where necessary to conform to the current year
presentation.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for all significant accounting policies of the reporting entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Short term investments - available for sale
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Short term investments - available for sale |
3. Short term investments - available for sale
The
Company classifies its short term investments as available for
sale. Short term investments comprise highly liquid
investments with maturities of greater than three months and
minimum “A+” rated fixed and floating rate
securities. The investments are reported at fair value
with unrealized gains or losses reported in a separate component of
shareholders’ equity. Any differences between the
cost and fair value of investments are represented by accrued
interest. The fair value of short term investments are represented
by level 1 fair value measurements – quoted prices in active
markets for identical assets.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Available For Sale Securities Disclosure No definition available.
|
|
Goodwill
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
4. Goodwill
The
Company has made a number of strategic acquisitions since its
inception to enhance its capabilities and experience in certain
areas of the clinical development process. Goodwill
arising on acquisition represents the excess of the cost of
acquired entities over the net amounts assigned to assets acquired
and liabilities assumed. Goodwill primarily comprises
acquired workforce in place which does not qualify for recognition
as an asset apart from goodwill.
The
Company tests goodwill annually for any impairments or whenever
events occur which may indicate impairment. The results
of the Company’s goodwill impairment testing during the year
ended December 31, 2011, indicated the existence of sufficient
headroom such that a reasonably possible change to the key
assumptions used would be unlikely to result in an impairment of
the related goodwill.
(a) Acquisition of Firecrest Clinical
On
July 14, 2011 the Company acquired 100% of the common stock of
Firecrest Clinical Limited (“Firecrest”), a market
leading provider of technology solutions that boost investigator
site performance and study management, for an initial cash
consideration of €17.0 million ($24.1million). Headquartered
in Limerick, Ireland, Firecrest Clinical provides a comprehensive
site performance management system that is used to improve
compliance consistency and execution of activities at investigative
sites. Further consideration of up to €33.0 million ($46.8
million) may become payable if certain performance milestones are
achieved in the period to June 30, 2013. At December 31, 2011 the
Company has recorded a liability of €31.3 million ($40.6
million) in relation to these performance milestones.
The
acquisition of Firecrest has been accounted for as a business
combination in accordance with FASB ASC 805 Business Combinations.
The following table summarizes the estimated fair values of the
assets acquired and the liabilities assumed:
Goodwill
represents the cost of an established workforce with experience in
the development of site performance and study management systems
and process related efficiencies expected to be generated from the
use of the Firecrest site performance management system and is not
tax deductable.
The
proforma effect of the Firecrest acquisition if completed on
January 1, 2010 would have resulted in net revenue, net income and
earnings per share for the fiscal years ended December 31, 2010 and
December 31, 2011 as follows:
(b) Acquisition of Oxford Outcomes
On
January 14, 2011 the Company acquired approximately 80% of the
common stock of Oxford Outcomes Limited (“Oxford
Outcomes”), a leading international health outcomes
consultancy business, for an initial cash consideration of
£17.8 million ($27.6 million). Headquartered in
Oxford, United Kingdom, and with offices in the USA and Canada,
Oxford Outcomes provides specialist services in the areas of
patient reported outcomes (PRO), health economics, epidemiology and
translation and linguistic validation. Further
consideration of up to £6.5 million ($10.1 million) may become
payable during the period to March 31, 2012 if certain performance
milestones are achieved. In July 2011 the Company paid
£3.3 million ($5.1 million) in respect of the first element of
this additional consideration. The Company has recorded a liability
of £3.2 million ($4.9 million) at December 31, 2011 in respect
of the remaining performance milestones. The acquisition
agreement also provided for certain working capital targets to be
achieved by Oxford Outcomes on completion. In May 2011
the Company paid an additional £3.3 million ($5.1 million) in
respect of certain elements of this review. A liability for a
further £0.8 million ($1.2 million) was recorded at December
31, 2011 relating to additional amounts payable in respect of the
remaining elements of this review.
On
January 14, 2011 a put and call option was also agreed between the
Company and the selling shareholders for the acquisition of the
remaining common stock of Oxford Outcomes during the year ended
December 31, 2011 for cash consideration of £3.8 million ($6.0
million). Further consideration of up to £1.5
million ($2.3 million) relating to this remaining common stock may
become payable during the period to March 31, 2012 if certain
performance milestones are achieved. On October 20, 2011
this option was exercised and £3.8 million ($6.0 million) was
paid by the Company to the selling shareholders together with a
further £0.7 million ($1.1 million) in respect of the first
element of amounts due in respect of the performance milestones.
The Company has recorded a liability of £0.8 million ($1.2
million) at December 31, 2011 in respect of the remaining
performance milestones.
The
acquisition of Oxford Outcomes has been accounted for as a business
combination in accordance with FASB ASC 805 Business Combinations.
The following table summarizes the estimated fair values of the
assets acquired and the liabilities assumed:
Goodwill
represents the cost of established workforce with experience in
specialist services in the areas of patient reported outcomes
(PRO), health economics, epidemiology and translation and
linguistic validation and is not tax
deductible.
The
proforma effect of the Oxford Outcomes acquisition if completed on
January 1, 2010 would have resulted in net revenue, net income and
earnings per share for the fiscal years ended December 31, 2010 and
December 31, 2011 as follows:
(c) Prior Period Acquisitions of Timaq Medical Imaging
On
May 17, 2010 the Company acquired Timaq Medical Imaging
(“Timaq”), a European provider of advanced imaging
services to the pharmaceutical and biotechnology industry located
in Zurich, Switzerland. The Company was acquired for an initial
cash consideration of CHF 1.3 million ($1.2 million), with
additional consideration of up to CHF 2.9 million ($2.6 million)
payable if certain performance milestones are achieved by the
Company. The Company accrued CHF 2.9 million ($2.6
million) in relation to the additional consideration at date of
acquisition.
On
November 5, 2010 the first element of these performance milestones
was achieved requiring deferred payments of CHF 0.3 million ($0.3
million) to the selling shareholders in each of the years ended
December 31, 2010, December 31, 2011 and December 31,
2012. As at December 31, 2011 CHF 0.6 million ($0.6
million) has been paid by the Company and a further CHF 0.3 million
($0.3 million) has been recorded as a liability in respect of the
2012 payment. Further consideration of up to CHF 2.0
million is payable if the remaining performance milestones are
achieved during the years ended December 31, 2010 to December 31,
2012. During the year ended December 31, 2011 the Company assessed
the likelihood of the remaining milestones being achieved as remote
and consequently has released CHF 2.0 million ($1.7 million)
previously accrued in relation to these milestones.
The
acquisition of Timaq has been accounted for as a business
combination in accordance with FASB ASC 805 Business Combinations.
The following table summarizes the fair values of the assets
acquired and the liabilities assumed:
Goodwill
represents the acquisition of an established workforce with
experience in the provision of advanced imaging services to
pharmaceutical and biotechnology customers in the European
market.
The
proforma effect of the Timaq Medical Imaging acquisition if
completed on January 1, 2009 would have resulted in net revenue,
net income and earnings per share for the fiscal years ended
December 31, 2009 and December 31, 2010 as follows:
(d) Prior Period Acquisitions - Acquisition of Healthcare
Discoveries Inc.
On
February 11, 2008 the Company acquired 100% of the common stock of
Healthcare Discoveries Inc. for an initial cash consideration of
$11.1 million, excluding costs of
acquisition. Healthcare Discoveries, located in San
Antonio, Texas, is engaged in the provision of Phase I clinical
trial services. Certain performance milestones were
built into the acquisition agreement requiring payment of
additional consideration of up to $10.0 million if these milestones
were achieved during the year ended December 31,
2008. On September 3, 2010 $2.2 million was paid to the
former shareholders of Healthcare Discoveries Inc. in full and
final settlement of the outstanding consideration
payable.
The
acquisition of Healthcare Discoveries has been accounted for as a
business combination in accordance with FASB Statement No. 141. The
following table summarizes the fair values of the assets acquired
and the liabilities assumed at the date of
acquisition.
Goodwill
represents the acquisition of an established workforce with
experience in the provision of Phase I clinical trial management
services to pharmaceutical and biotechnology
companies.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for goodwill. No definition available.
|
|
Intangible Assets
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible Assets |
5. Intangible Assets
On
July 14, 2011 the Company acquired 100% of the common stock of
Firecrest Clinical Limited, a market leading provider of technology
solutions that boost investigator site performance and study
management. The value of certain technology assets and customer
relationships identified of $11.2 million and $5.2 million
respectively are being amortized over approximately 7.5 years, the
estimated period of benefit. The value of certain tradenames and
order backlog identified of $1.4 million and $1.2 million
respectively are being amortized over approximately 4.5 and 1.2
years, the estimated period of benefit. $1,486,000 has
been amortized in the period since the date of
acquisition.
On
January 14, 2011 the Company acquired approximately 80% of the
common stock of Oxford Outcomes Limited, a leading international
health outcomes consultancy business. The value of certain customer
relationships and order backlog identified of $6.6 million and $0.6
million respectively are being amortized over approximately 6.5 and
2 years, the estimated period of
benefit. $1,087,000 has been amortized in the
period since the date of acquisition. A put and call option was
also agreed between the Company and the selling shareholders for
the acquisition of the remaining common stock of Oxford Outcomes
Limited.
On
May 17, 2010 the Company acquired Timaq Medical Imaging, a European
provider of advanced imaging services. The value of
certain client relationships identified of $0.8 million is being
amortized over approximately 3 years, the estimated period of
benefit. $417,000 has been amortized in the period since
the date of acquisition.
During
the year ended December 31, 2009 the Company completed the
acquisitions of Qualia Clinical Services, Inc, a US provider of
Phase I clinical trial services and Veeda Laboratories Limited, a
specialist provider of biomarker laboratory services. The value of
certain client relationships identified of $0.4 million is being
amortized over approximately 3 years, the estimated period of
benefit. $330,000 has been amortized in the period since
the date of acquisition.
On
July 1, 2004 the Company acquired 70% of the common stock of Beacon
Biosciences Inc, a US provider of advanced imaging
services. On December 31, 2008 the remaining 30% of the
common stock was acquired by the Company. The value of
certain customer relationships and order backlog identified of $0.2
million and $1.5 million respectively are being amortized over
approximately 3 years, the estimated period of
benefit. $1,710,000 has been amortized in the period
since the date of acquisition.
On
November 14, 2008 the Company acquired Prevalere Life Sciences, a
US provider of bioanalytical
and immunoassay laboratory services. The value of
certain customer relationships identified of $7.4 million is being
amortized over periods ranging from approximately 7 to 11 years,
the estimated period of the benefit. $2,532,000 has been
amortized in the period since the date of acquisition.
On
February 11, 2008 the Company acquired Healthcare Discoveries, a US
provider of Phase I clinical trial services. The value
of certain client relationships identified of $1.6 million is being
amortized over periods ranging from approximately 2 to 9 years, the
estimated periods of benefit. The value of certain
volunteer lists identified of $1.3 million is being amortized over
approximately 6 years, the estimated period of
benefit. $1,896,000 has been amortized in the period
since the date of acquisition.
Future
intangible asset amortization expense for the years ended December
31, 2012 to December 31, 2016 is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for all or part of the information related to intangible assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Property, Plant and Equipment, net
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment, net |
6. Property, Plant and Equipment, net
Total
cost at December 31, 2011 includes $nil (2010: $825,000), which
relates to assets held under capital finance leases. Related
accumulated depreciation amounted to $nil (2010:
$518,000).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Other Liabilities
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities |
7. Other Liabilities
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for other liabilities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Other Non-Current Liabilities
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Non-Current Liabilities |
8. Other Non-Current Liabilities
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period. No definition available.
|
|
Employee Benefits
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Employee Benefits |
9. Employee Benefits
Certain
Company employees are eligible to participate in a defined
contribution plan (the "Plan"). Participants in the Plan may elect
to defer a portion of their pre-tax earnings into a pension plan,
which is run by an independent party. The Company matches
participant's contributions typically at 6% of the participant's
annual compensation. Contributions to this plan are recorded, as an
expense in the Consolidated Statement of Operations. Contributions
for the years ended December 31, 2009, December 31, 2010 and
December 31, 2011 were $14,241,000, $14,206,000 and $16,644,000
respectively.
The
Company's United States operations maintain a retirement plan (the
"U.S. Plan") that qualifies as a deferred salary arrangement under
Section 401(k) of the Internal Revenue Code. Participants in the
U.S. Plan may elect to defer a portion of their pre-tax earnings,
up to the Internal Revenue Service annual contribution limit. The
Company matches 50% of each participant's contributions; each
participant can contribute up to 6% of their annual compensation.
Contributions to this U.S. Plan are recorded, in the year
contributed, as an expense in the Consolidated Statement of
Operations. Contributions for the years ended December 31, 2009,
December 31, 2010 and December 31, 2011 were $5,189,000, $6,603,000
and $7,064,000 respectively.
One
of the Company’s subsidiaries which was acquired during the
2003 fiscal year, ICON Development Solutions Limited, operates a
defined benefit pension plan in the United Kingdom for its
employees. The plan is managed externally and the related pension
costs and liabilities are assessed in accordance with the advice of
a professionally qualified actuary. Plan assets at December 31,
2011, December 31, 2010 and December 31, 2009, consist of units
held in independently administered funds. The pension costs of this
plan are presented in the following tables in accordance with the
requirements of ASC 715-60, Defined Benefit Plans –
Other Postretirement. The plan has been closed to new
entrants with effect from July 1, 2003.
The
fair values of the assets above do not include any of the
Company’s own financial instruments, property occupied by, or
other assets used by, the Company.
The
following assumptions were used at the commencement of the year in
determining the net periodic pension benefit cost/(credit) for the
years ended December 31, 2009, December 31, 2010 and December 31,
2011:
The
estimated net gain and prior service cost for the defined benefit
pension plan that will be amortized from accumulated other
comprehensive income into net periodic benefit cost over the next
year are $nil and $nil respectively.
Amounts
recognized in accumulated other comprehensive income that has not
yet been recognized as components of net periodic benefit cost are
as follows:
Benefit Obligation
The
following assumptions were used in determining the benefit
obligation at December 31, 2011:
The
discount rate is determined by reference to UK long dated
government and corporate bond yields at the balance sheet
date. This is represented by the iboxx AA 15 year plus
return.
Plan Assets
The
assets of the scheme are invested in the Legal and General Global
Equity and Fixed Index Fund. The aim of this fund is to
capture the returns on UK and overseas equity markets with a more
even investment in UK and overseas equities than would be provided
by reference to market capitalization or consensus
weights.
The
expected long-term rate of return on assets at December 31, 2011 of
5.8% was calculated as the value of the fund after application of a
market value reduction factor.
At
December 31, 2011 UK gilts were yielding around 2.8% per annum.
This is often referred to as the risk free rate of return as UK
gilts have a negligible risk of default and the income payments and
capital on redemption are guaranteed by the UK
Government. The long-term expected return on equities
has been determined by setting appropriate risk premiums above the
yield on UK gilts. A long term equity
“risk-premium” of 3.1% per annum has been assumed, this
being the expected long-term out-performance of equities over UK
gilts. The long-term expected return on bonds is
determined by reference to UK long dated government and corporate
bond yields at the balance sheet date. This is
represented by the iboxx AA 15 year plus return.
The
expected long term rates of return on different asset classes over
the long term are as follows:
The
underlying asset split of the fund is shown below.
Applying
the above expected long term rates of return to the asset
distribution at December 31, 2011, gives rise to an expected
overall rate of return of scheme assets of approximately 5.8% per
annum.
Plan Asset Fair Value Measurements
Cash Flows
The
Company expects to contribute $0.3 million to its pension fund in
the year ending December 31, 2012.
The
following annual benefit payments, which reflect expected future
service, as appropriate, are expected to be paid.
The
expected cash flows are estimated figures based on the members
expected to retire over the next 10 years assuming no early
retirements plus an additional amount in respect of recent average
withdrawal experience. At the present time it is not
clear whether annuities will be purchased when members reach
retirement or whether pensions will be paid each month out of
scheme assets. The cash flows above have been estimated
on the assumption that pensions will be paid monthly out of scheme
assets. If annuities are purchased, then the expected
benefit payments will be significantly different from those shown
above.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for pension and other postretirement benefits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Share Options and Stock Compensation Charges
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share Options and Stock Compensation Charges |
10. Share Options and Stock Compensation Charges
On
July 21, 2008 the Company adopted the Employee Share Option Plan
2008 (the “2008 Employee Plan”) pursuant to which the
Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any employee, or any
director holding a salaried office or employment with the Company
or a Subsidiary for the purchase of ordinary shares. On the same
date, the Company also adopted the Consultants Share Option Plan
2008 (the “2008 Consultants Plan”), pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may grant options to any consultant, adviser or
non-executive director retained by the Company or any Subsidiary
for the purchase of ordinary shares.
Each
option granted under the 2008 Employee Plan or the 2008 Consultants
Plan (together the “2008 Option Plans”) will be an
employee stock option, or NSO, as described in Section 422 or 423
of the Internal Revenue Code. Each grant of an option under the
2008 Options Plans will be evidenced by a Stock Option Agreement
between the optionee and the Company. The exercise price will be
specified in each Stock Option Agreement, however option prices
will not be less than 100% of the fair market value of an ordinary
share on the date the option is granted.
An
aggregate of 6.0 million ordinary shares have been reserved under
the 2008 Employee Plan as reduced by any shares issued or to be
issued pursuant to options granted under the 2008 Consultants Plan,
under which a limit of 400,000 shares applies. Further,
the maximum number of ordinary shares with respect to which options
may be granted under the 2008 Employee Option Plan, during any
calendar year to any employee shall be 400,000 ordinary
shares. There is no individual limit under the 2008
Consultants Plan. No options may be granted under
the 2008 Option Plans after July 21, 2018.
On
July 21, 2008 the Company adopted the 2008 Employees Restricted
Share Unit Plan (the “2008 RSU Plan”) pursuant to which
the Compensation and Organization Committee of the Company’s
Board of Directors may select any employee, or any director holding
a salaried office or employment with the Company or a Subsidiary to
receive an award under the plan. An aggregate of 1.0
million ordinary shares have been reserved for issuance under the
2008 RSU Plan.
On
January 17, 2003 the Company adopted the Share Option Plan 2003
(the “2003 Share Option Plan”) pursuant to which the
Compensation and Organization Committee of the Board may grant
options to officers and other employees of the Company or its
subsidiaries for the purchase of ordinary shares. Each
grant of an option under the 2003 Share Option Plan will be
evidenced by a Stock Option Agreement between the employee and the
Company. The exercise price will be specified in each Stock Option
Agreement.
An
aggregate of 6.0 million ordinary shares have been reserved under
the 2003 Share Option Plan; and, in no event will the number of
ordinary shares that may be issued pursuant to options awarded
under the 2003 Share Option Plan exceed 10% of the outstanding
shares, as defined in the 2003 Share Option Plan, at the time of
the grant, unless the Board expressly determines otherwise.
Further, the maximum number of ordinary shares with respect to
which options may be granted under the 2003 Share Option Plan
during any calendar year to any employee shall be 400,000 ordinary
shares. No options can be granted after January 17,
2013.
Share
option awards are granted with an exercise price equal to the
market price of the Company’s shares at date of
grant. Share options typically vest over a period of
five years from date of grant and expire eight years from date of
grant. The maximum contractual term of options
outstanding at December 31, 2011 is eight years.
The
following table summarizes the transactions for the Company’s
share option plans for the years ended December 31, 2011, December
31, 2010 and December 31, 2009:
The
weighted average remaining contractual life of options outstanding
and options exercisable at December 31, 2011, was 4.68 years and
3.26 years respectively. 854,424 options are expected to vest
during the year ended December 31, 2012.
The
intrinsic value of options exercised during the year ended December
31, 2011 amounted to $2.9 million. The intrinsic value
of options outstanding and options exercisable at December 31, 2011
amounted to $6.0 million and $5.9 million
respectively. Intrinsic value is calculated based on the
market value of the Company’s shares at December 31,
2011.
Non
vested shares outstanding as at December 31, 2011 are as
follows:
Outstanding and exercisable share options:
The
following table summarizes information concerning outstanding and exercisable share
options as of December 31, 2011:
Options
granted at exercise prices ranging from $8.60 to $18.00 have fully
vested at December 31, 2011. Substantially all options vest over a
five year period from the date of grant.
Fair value of Stock Options Assumptions
The
weighted average fair value of options granted during the years
ended December 31, 2011, December 31, 2010 and December 31, 2009
was calculated using the Black-Scholes option pricing
model. The weighted average fair values and assumptions
were as follows:
Expected
volatility is based on the historical volatility of our common
stock over a period equal to the expected term of the options; the
expected life represents the weighted average period of time that
options granted are expected to be outstanding given consideration
to vesting schedules, and our historical experience of past vesting
and termination patterns. The risk-free rate is based on the U.S.
government zero-coupon bonds yield curve in effect at time of the
grant for periods corresponding with the expected life of the
option.
Restricted Share Units
The
Company has awarded restricted Share Units
(“RSU’s”) to certain key executives of the
Group. Details of RSU’s granted during the year
ended December 31, 2011 were as follows:
*
includes 100,000 RSU’s awarded to Mr. Peter Gray which are
not expected to vest following his retirement as CEO of the Company
on September 30, 2011.
The
Company also awarded RSU’s in prior periods. On
August 7, 2008 the Company awarded 6,280 RSU’s to certain key
employees of the Group. These RSU’s vested over
periods ranging from February 26, 2009 to February 26,
2011. The market value of the Company’s ordinary
shares on date of award was $41.95. On August 16, 2010
the Company issued 2,512 ordinary shares relating to certain of
these RSU awards. On May 20, 2011 the Company issued a
further 3,768 ordinary shares relating to the remaining RSU
awards.
The
following table summarizes the movement in non-vested RSU’s
during the year ended December 31, 2011:
The
fair value of stock awards vested for the year ended December 31,
2011 totaled $0.1 million (2010: $0.1 million).
Non-cash stock compensation expense
Income
from operations for the year ended December 31, 2011 is stated
after charging $9.4 million in respect of non-cash stock
compensation expense. Non-cash stock compensation
expense for the year ended December 31, 2011 has been allocated to
direct costs and selling, general and administrative expenses as
follows:
Total
non-cash stock compensation expense not yet recognized at December
31, 2011 amounted to $20.6 million. The weighted average
period over which this is expected to be recognized is 3.0
years. Total tax benefit recognized in additional paid
in capital related to the non-cash compensation expense amounted to
$0.7 million for the year ended December 31, 2011 (2010: $2.3
million, 2009: $0.5 million).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Government Grants
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Government Grants |
11. Government Grants
Capital
grants received may be refundable in full if certain events occur.
Such events, as set out in the related grant agreements, include
sale of the related asset, liquidation of the Company or failure to
comply with other conditions of the grant agreements. No
loss contingency has been recognized as the likelihood of such
events arising has been assessed as remote. Government
grants amortized to the profit and loss account amounted to
$115,000 and $220,000 for the years ended December 31, 2011 and
December 31, 2010 respectively. As at December 31,
2011 the Company had $1.4 million in restricted retained earnings,
pursuant to the terms of grant agreements.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Government Grants Disclosure No definition available.
|
|
Share Capital
|
12 Months Ended |
|---|---|
|
Dec. 31, 2011
|
|
| Share Capital |
12. Share Capital
Holders
of ordinary shares will be entitled to receive such dividends as
may be recommended by the board of directors of the Company and
approved by the shareholders and/or such interim dividends as the
board of directors of the Company may decide. On liquidation or a
winding up of the Company, the par value of the ordinary shares
will be repaid out of the assets available for distribution among
the holders of the ordinary shares of the Company. Holders of
ordinary shares have no conversion or redemption rights. On a show
of hands, every holder of an ordinary share present in person or
proxy at a general meeting of shareholders shall have one vote, for
each ordinary share held with no individual having more than one
vote.
During
the year ended December 31, 2009, 489,370 options were exercised by
employees at an average exercise price of $9.03 per share for total
proceeds of $4.4 million.
During
the year ended December 31, 2010, 1,237,015 options were exercised
by employees at an average exercise price of $10.64 per share for
total proceeds of $13.2 million. During the year ended
December 31, 2010 2,512 ordinary shares were issued in respect of
certain RSU’s previously awarded by the Company.
During
the year ended December 31, 2011, 430,340 options were exercised by
employees at an average exercise price of $10.84 per share for
total proceeds of $4.7 million. During the year ended December 31,
2010 3,768 ordinary shares were issued in respect of certain
RSU’s previously awarded by the Company. All ordinary shares
repurchased by the Company were cancelled, and the nominal value of
these shares is transferred to a capital redemption reserve fund as
required under Irish Company Law.
Share Repurchase Program
On
October 27, 2011 the Company announced its intention to commence a
share repurchase program of up to $50 million. On November 22, 2011
the Company entered into two separate share repurchase plans of $10
million each, covering the periods November 23, 2011 to December
31, 2011 and January 1, 2012 to February 20, 2012
respectively. The Company intends to enter further share
repurchase plans, to effect the share repurchase program in
accordance with Rule 10b-18 and Rule 10b5-1 of the Securities
Exchange Act of 1934, the authorization granted at the
Company’s annual general meeting on July, 18 2011, applicable
laws and regulations and the Listing Rules of the Irish Stock
Exchange.
Under
the repurchase program, a broker will purchase the Company’s
American Depositary Shares (“ADSs”) from time to time
on the open market or in privately negotiated transactions in
accordance with agreed terms and limitations. ADSs
purchased will be deposited with the Depositary under the
Company’s ADR facility against delivery of the underlying
Ordinary Shares, which will be repurchased by the Company on the
Irish Stock Exchange in compliance with the Company’s share
repurchase authorization and applicable laws and
regulations. Separately, Ordinary Shares traded on the Irish
Stock Exchange may also be repurchased on behalf of the
Company.The program is designed to allow share repurchases
during periods when the Company would ordinarily not be permitted
to do so because it may be in possession of material non-public or
price-sensitive information, applicable insider trading laws or
self-imposed trading blackout periods. The Company’s instructions to the broker are
irrevocable and the trading decisions in respect of the
repurchase program will be made independently of and uninfluenced
by the Company. The Company confirms that on entering
the two repurchase plans on November 22, 2011 it had no material
non-public,
price-sensitive or inside
information regarding the Company or its securities. Furthermore,
the Company will not enter into additional plans whilst in
possession of such information.
The
timing and actual number of shares repurchased will be dependent on
market conditions, legal and regulatory requirements and the other
terms and limitations contained in the plans. In
addition, share repurchases may be suspended or discontinued in
certain circumstances in accordance
with the agreed terms. Therefore, there can be no
assurance as to the timing or number of shares that may be
repurchased under the repurchase program. All
Ordinary Shares repurchased by the Company will be
cancelled. The Company currently intends to complete
repurchases within a 12 month period.
During
the year ended December 31, 2011 545,597 ordinary shares were
repurchased by the Company for a total consideration of $9.0
million. All ordinary shares repurchased by the Company
were cancelled, and the nominal value of these shares transferred
to a capital redemption reserve fund as required under Irish
Company Law.
|
| X | ||||||||||
|
- Definition
The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Income Taxes
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income Taxes |
13. Income Taxes
The
Company’s United States and Irish based subsidiaries file tax
returns in the United States and Ireland respectively. Other
foreign subsidiaries are taxed separately under the laws of their
respective countries.
The
components of income before provision for income tax expense are as
follows:
The
components of total income tax expense are as follows:
Ireland’s
statutory income tax rate is 12.5%. The Company’s
consolidated effective tax rate differed from the statutory rate as
set forth below;
The
tax effects of temporary differences that give rise to significant
portions of deferred tax assets and deferred tax liabilities are
presented below:
$10.1
million (2010:$10.0 million) of the deferred tax asset of $24.7
million (2010:$16.7 million) above is non-current. $20.4
million (2010:$13.9 million) of the deferred tax liability of $21.6
million (2010:$15.9 million) is non-current.
At
December 31, 2011 non-U.S subsidiaries had operating loss carry
forwards for income tax purposes that may be carried forward
indefinitely, available to offset against future taxable income, if
any, of approximately $83.1 million (2010:$43.3 million). At
December 31, 2011 non-U.S. subsidiaries also had additional
operating loss carry forwards of $5.6 million which are due to
expire between 2012 and 2014.
At
December 31, 2011 ICON Central Laboratories Inc., a U.S.
subsidiary, had U.S. Federal and State net operating loss
(“NOL”) carry forwards of approximately $4.9 million
and $13.1 million, respectively. These net operating losses are
available for offset against future taxable income and expire
between 2012 and 2031. Of the $4.9 million U.S. Federal
and $13.1 million State net operating losses, approximately $3.9
million and $12.1 million are
currently available for offset against future U.S. Federal and
State taxable income respectively. Annual utilization of these
state net operating losses may be limited by specific state rules.
The subsidiary’s ability to use the remaining U.S. Federal
and State net operating loss carry forwards of $1.0 million and
$1.0 million, respectively is further limited to
$113,000 per
year due to the subsidiary experiencing a change of ownership in
2000, as defined by Section 382 of the Internal Revenue Code of
1986, as amended.
The
expected expiry dates of these losses are as follows:
In
addition, ICON Central Laboratories Inc has alternative minimum tax
credit carry forwards of approximately $0.3 million that are
available to reduce future U.S. federal regular income taxes, over
an indefinite period. It also has general business
credit carry forwards of approximately $0.3 million that are
available to offset future U.S. federal income taxes.
At
December 31, 2011 ICON Clinical Research Inc. and its U.S.
subsidiaries had U.S. State net loss and credit forwards of
approximately $1.2 million. These net operating losses are
available for offset against future, or in some cases prior,
taxable income in the relevant state and generally expire between
2020 and 2031.
The
expected expiry dates of these losses are as follows:
ICON
Clinical Research, Inc. has tax credit carry forwards of
approximately U.S. $0.1 million that are available to reduce future
income taxes, if any. These credits begin to expire in
2012 and are subject to an annual limitation that will prevent full
utilization before expiration.
At
December 31, 2011 Oxford Outcomes, Inc., a U.S. subsidiary, had
U.S. Federal and State net operating loss carry forwards of
approximately $0.8 million and $0.9 million, respectively. These
net operating losses are available for offset against future, or in
some cases prior, taxable income in the relevant state and
generally expire between 2030 and 2032.
The
expected expiry dates of these losses are as follows:
The
valuation allowance at December 31, 2011 was approximately $16.4
million. The valuation allowance for deferred tax assets
as of December 31, 2010 and December 31, 2009 was $12.3 million and
$10.4 million respectively. The net change in the total valuation
allowance was an increase of $4.1 million during 2011 and an
increase of $1.9 million during 2010.
The
valuation allowances at December 31, 2011 and December 31, 2010
were primarily related to tax losses and tax credits carried
forward that, in the judgment of management, are not more likely
than not to be realized. In assessing the realizability of deferred
tax assets, management considers whether it is more likely than not
that some portion or all of the deferred tax assets will not be
realized. The ultimate realization of deferred tax assets is
dependent upon the generation of future taxable income during the
periods in which those temporary differences become deductible.
Management considers the scheduled reversal of deferred tax
liabilities, projected future taxable income, and tax planning
strategies in making this assessment.
The
Company has not recognized a deferred tax liability for the
undistributed earnings of foreign subsidiaries that arose in 2011
and prior years as the Company considers these earnings to be
indefinitely reinvested.
A
reconciliation of the beginning and ending amount of total
unrecognized tax benefits is as follows:
The
Company does not anticipate that the amount of unrecognized tax
benefits at December 31, 2011 will significantly change in the
coming year.
Included
in the balance of total unrecognized tax benefits at December 31,
2011 there were net potential benefits of $6.5 million, which if
recognized, would affect the effective rate on income tax from
continuing operations. The balance of total unrecognized tax
benefits at December 31, 2010 and December 31, 2009 included net
potential benefits which, if recognized, would affect the effective
rate of income tax from continuing operations of $8.1 million and
$15.4 million respectively.
Interest
and penalties recognized as a net benefit during the year ended
December 31, 2011 amounted to $0.4 million (2010: $1.8 million) and
are included within the provision for income
taxes. Total accrued interest and penalties as of
December 31, 2010 and December 31, 2009 were $1.2 million and $1.7
million respectively and are included in the closing income tax
liabilities at those dates.
Our
major tax jurisdictions are the United States and
Ireland. We may potentially be subjected to tax audits
in our major jurisdictions. In the United States tax
periods open to audit include the years ended December 31, 2008,
December 31, 2009, December 31, 2010 and December 31,
2011. In Ireland tax periods open to audit include the
years ended December 31, 2007, December 31, 2008, December 31,
2009, December 31, 2010 and December 31, 2011. During
such audits, local tax authorities may challenge the positions
taken by us in tax returns.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Non-recurring charges, net
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-recurring charges, net |
14. Non-recurring charges, net
Non-recurring
charges, net recognized during the year ended December 31, 2011
comprise:
Restructuring Charges
During
the three months ended March 31, 2011 the Company commenced a
review of its operations to improve resource utilization within the
business and better align resources to current and future growth
opportunities of the business. This review resulted in
the adoption of an initial restructuring plan (the “Q1
Restructuring Plan”), which resulted in the closure of the
Company’s facility in Edinburgh, United Kingdom and resource
rationalizations in certain of the more mature markets in which it
operates. A restructuring charge of $5.0 million was
recognized in respect of this plan during the three months ended
March 31, 2011, $1.0 million in respect of lease termination and
exit costs associated with the closure of the Edinburgh facility
and $4.0 million in respect of workforce reductions. $3.5 million
of costs recognised under the Q1 Restructuring Plan related to the
clinical research segment, while $1.5 million related to our
central laboratory business.
During
the three months ended September 30, 2011 the Company implemented a
further restructuring plan (the “Q3 Restructuring
Plan”) which resulted in the relocation of the
Company’s facility in Maryland, USA; and further resource
rationalizations. A restructuring charge of $4.8 million
was recognized in respect of this plan during the three months
ended September 30, 2011, $0.9 million in respect of lease
termination and exit costs associated with the closure of the
existing Maryland facility and $3.9 million in respect of workforce
reductions. All costs recognized under the Q3
Restructuring Plan related to the clinical research
segment.
Details
of the movement in the 2011 Restructuring Plan recognized during
the year ended December 31, 2011 is as follows:
During
the year ended December 31, 2009 the Company also conducted a
review of its operations in response to the globalization of
clinical studies and its attendant impact on resources in existing
and emerging markets. This review resulted in the
adoption of a restructuring plan (the “2009 Restructuring
Plan”) which resulted in resource rationalizations in certain
of the more mature markets in which the Company operates and the
closure of certain of the Company’s office
facilities. A restructuring charge of $13.4 million was
recognised, $8.5 million in respect of office consolidations and
$4.9 million in respect of workforce reductions. $12.9 million of
these costs recognised under this plan related to our clinical
research segment while $0.5 million related to our central
laboratory business.
Details
of movement in the 2009 Restructuring Plan recognized during the
years ended December 31, 2009 to December 2011 is as
follows:
Research and Development Tax Incentives
During
the year ended December 31, 2009 the Company received research and
development incentives in certain jurisdictions in which it
operates. Research and development credits are available
to the Company under the tax laws in certain jurisdictions, based
on qualifying research and development spend as defined under those
tax laws. Research and development credits are generally recognized
as a reduction of income tax expense. However, certain tax
jurisdictions provide refundable credits that are not wholly
dependent on the Company’s ongoing income tax status or
income tax position. In these circumstances the benefit of these
credits is not recorded as a reduction to income tax expense, but
rather as a reduction of the operating expenditure to which the
credits relate. During the year ended December 31, 2009 the Company
recognized income of $4.5 million in respect of research and
development tax incentives received during the current year but
related to prior years.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Significant Concentrations
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Significant Concentrations |
15. Significant Concentrations
The
Company does business with most major international pharmaceutical
companies. Provision for doubtful debts at December 31, 2011
comprises:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Commitments and Contingencies
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Commitments and Contingencies |
16. Commitments and Contingencies
Litigation
The
Company is not party to any litigation or other legal proceedings
that the Company believes could reasonably be expected to have a
material adverse effect on the Company's business, results of
operations and financial condition.
Operating Leases
The
Company has several non-cancelable operating leases, primarily for
facilities, that expire over the next 10 years. These leases
generally contain renewal options and require the Company to pay
all executory costs such as maintenance and insurance. The Company
recognized $52.2 million, $46.0 million and $45.2 million in rental
expense for the years ended December 31, 2011, December 31, 2010
and December 31, 2009 respectively. Future minimum rental
commitments for operating leases with non-cancelable terms in
excess of one year are as follows:
Share Repurchase Program
On
October 27, 2011 the Company announced its intention to commence a
share repurchase program of up to $50 million. On November 22, 2011
the Company entered into two separate share repurchase plans of $10
million each, covering the periods November 23, 2011 to December
31, 2011 and January 1, 2012 to February 20, 2012
respectively. The Company intends to enter further share
repurchase plans, to effect the share repurchase program in
accordance with Rule 10b-18 and Rule 10b5-1 of the Securities
Exchange Act of 1934, the authorization granted at the
Company’s annual general meeting on July, 18 2011, applicable
laws and regulations and the Listing Rules of the Irish Stock
Exchange. At December 31, 2011 $10.0 million remains outstanding
under the above repurchase plans.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for commitments and contingencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Business Segment Information
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Segment Information |
17. Business Segment Information
The
Company is a contract research organization (“CRO”),
providing outsourced development services on a global basis to the
pharmaceutical, biotechnology and medical device industries. It
specializes in the strategic development, management and analysis
of programs that support all stages of the clinical development
process - from compound selection to Phase I-IV clinical
studies. The Company has the expertise and capability to
conduct clinical trials in most major therapeutic areas on a global
basis and has the operational flexibility to provide development
services on a stand-alone basis or as part of an integrated
“full service” solution. The Company has
expanded predominately through internal growth, together with a
number of strategic acquisitions to enhance its expertise and
capabilities in certain areas of the clinical development
process. The Company also provides laboratory services
through its central laboratory business, which includes the
Company’s central laboratories located in Dublin, New York,
India, Singapore and China.
The
Company determines and presents operating segments based on the
information that is internally provided to the Chief Executive
Officer and Chief Financial Officer, who together are considered
the Company’s chief operating decision maker, in accordance
with FASB ASC 280-10 Disclosures about Segments of
an Enterprises and Related Information. The Company has
determined that it has two reportable segments, its Clinical
Research segment and Central Laboratory segment.
The
Company's areas of operation outside of Ireland principally include
the Ireland, United States, United Kingdom, France, Germany, Italy,
Spain, The Netherlands, Sweden, Finland, Denmark, Belgium,
Switzerland, Poland, Czech Republic, Lithuania, Latvia, Russia,
Ukraine, Hungary, Israel, Romania, Canada, Mexico, Brazil,
Colombia, Argentina, Chile, Peru, India, China, South Korea, Japan,
Thailand, Taiwan, Singapore, The Philippines, Australia, New
Zealand, and South Africa.
Segment
information as at December 31, 2011 and December 31, 2010 and for
the years ended December 31, 2011, December 31, 2010 and December
31, 2009 is as follows:
a) The
distribution of net revenue by geographical area was as
follows:
g) The
distribution of depreciation and amortization by geographical area
was as follows:
h) The
distribution of depreciation and amortization by business segment
was as follows:
i) The
distribution of total assets by geographical area was as
follows:
j)
The distribution of total assets by business segment was as
follows:
k)
The distribution of capital expenditures by geographical area was
as follows:
l)
The distribution of capital expenditures by business segment was as
follows:
m)
The following table sets forth the clients which represented 10% or
more of the Company's net revenue in each of the periods set out
below.
*
Net revenue did not exceed 10%.
n)
The distribution of interest income by geographical area was as
follows:
o)
The distribution of interest income by business segment was as
follows:
p)
The distribution of the tax charge by geographical area was as
follows:
q)
The distribution of the tax charge by business segment was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Supplemental Disclosure of Cash Flow Information
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Supplemental Disclosure of Cash Flow Information |
18. Supplemental Disclosure of Cash Flow Information
*
recorded within interest expense
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Accumulated Other Comprehensive Income
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accumulated Other Comprehensive Income |
19. Accumulated Other Comprehensive Income
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Disclosure of the components of accumulated other comprehensive income (loss). No definition available.
|
|
Impact of New Accounting Pronouncements
|
12 Months Ended |
|---|---|
|
Dec. 31, 2011
|
|
| Impact of New Accounting Pronouncements |
20. Impact of New Accounting Pronouncements
In
December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures
about Offsetting Assets and Liabilities. ASU 2011-11
requires an entity to disclose information about offsetting and
related arrangements to enable users of financial statements to
understand the effect of those arrangements on its financial
position, and to allow investors to better compare financial
statements prepared under U.S. GAAP with financial statements
prepared under International Financial Reporting Standards (IFRS).
ASU 2011-11 is effective retrospectively for fiscal years beginning
after January 1, 2013.
In
September 2011, the FASB issued ASU No. 2011-08 Intangibles -
Goodwill and Other (Topic 350): Testing Goodwill for
Impairment. ASU 2011-08 permits an entity to make a
qualitative assessment of whether it is more likely than not that a
reporting unit’s fair value is less than its carrying amount
before applying the two-step goodwill impairment test. If an entity
concludes it is not more likely than not that the fair value of a
reporting unit is less than its carrying amount, it need not
perform the two-step impairment test. ASU 2011- 08 is effective for
fiscal years beginning after December 15, 2011.
In
June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income
(Topic 220): Presentation of Comprehensive
Income. ASU 2011-05 permits an entity to present the
components of net income and comprehensive income in either one or
two consecutive financial statements. The ASU eliminates the option
in U.S. GAAP to present other comprehensive income in the statement
of changes in equity. An entity should apply the ASU
retrospectively. ASU 2011-05 is effective for fiscal years ending
after December 15, 2012. In December 2011, the FASB decided to
defer the effective date of those changes in ASU 2011-05 that
relate only to the presentation of reclassification adjustments in
the statement of income by issuing ASU 2011-12, Comprehensive Income (Topic
220): Deferral of
the Effective Date for Amendments to the Presentation of
Reclassifications of Items Out of Accumulated Other Comprehensive
income in Accounting Standards Update 2011-05. The Company
plans to implement the provisions of ASU 2011-05 by presenting a
separate statement of other comprehensive income following the
statement of income in 2012.
In
May 2011, the FASB issued ASU No. 2011-04, Fair Value Measurement
(Topic 820): Amendments to Achieve Common
Fair Value Measurement and Disclosure Requirements in U.S. GAAP and
IFRSs. ASU 2011-04 provides guidance about how fair value
should be applied where it already is required or permitted under
IFRS or U.S. GAAP. For U.S. GAAP, most of the changes are
clarifications of existing guidance or wording changes to align
with IFRS. ASU 2011- 04 is effective prospectively for interim and
annual periods beginning after December 15, 2011.
In
December 2010, the FASB issued ASU No. 2010-28, Intangibles—Goodwill
and Other (Topic 350): When to Perform Step 2 of the
Goodwill Impairment Test for Reporting Units with Zero or Negative
Carrying Amounts, a consensus of the FASB Emerging Issues Task
Force (Issue No. 10-A). ASU 2010-28 modifies Step
1 of the goodwill impairment test under ASC Topic 350 for reporting
units with zero or negative carrying amounts to require an entity
to perform Step 2 of the goodwill impairment test if it is more
likely than not that a goodwill impairment exists. In determining
whether it is more likely than not that a goodwill impairment
exists, an entity should consider whether there are adverse
qualitative factors in determining whether an interim goodwill
impairment test between annual test dates is necessary. ASU No.
2010-28 is effective for fiscal years beginning after December 15,
2010.
|
| X | ||||||||||
|
- Definition
New And Recent Accounting Pronouncements Disclosure No definition available.
|
|
Related Parties
|
12 Months Ended |
|---|---|
|
Dec. 31, 2011
|
|
| Related Parties |
21. Related Parties
On
December 31, 2009 Dr. John Climax retired as Chairman of the Board
of the Company. From January 2010 he has held the
position as an outside director of the Company. The
Company has entered into a three year agreement with Rotrua
Limited, a company controlled by Dr. Climax, for the provision of
consultancy services at an agreed fee of €262,500 ($348,968)
per annum. The consultancy agreement provides that the
Company will provide during the term of the agreement permanent
disability and life insurance cover for Dr. Climax and medical
insurance cover for himself and his dependants.
|
| X | ||||||||||
|
- Definition
The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Subsequent Events
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Subsequent Events |
22. Subsequent Events
Acquisition of BeijingWits Medical Limited
On
February 15, 2012 the Company acquired 100% of the common stock of
BeijingWits Medical Limited (“BeijingWits”), a leading
Chinese CRO, for an initial cash consideration of $9.0
million.
BeijingWits
offers full-service clinical development capabilities and has a
strong track record in clinical trial execution in China. It is a
renowned expert in Chinese regulatory processes and a leading
advocate of International Conference on Harmonisation Good Clinical
Practice (“ICH GCP”) in China. In addition to boosting
the Company’s service capabilities in the region, BeijingWits
will also strengthen the Company’s presence through the
addition of over 100 highly qualified and experienced professionals
in Beijing, Shanghai, Chengdu, Guangzhou, Wuhan and Hong
Kong.
Further
consideration of up to $7.0 million may become payable if certain
performance milestones are achieved in the period to December 31,
2013.
The
following table summarizes the Company’s provisional
estimates of the fair values of assets acquired and the liabilities
assumed:
Acquisition of PriceSpective LLC
On
February 28, 2012 the Company acquired 100% of the common stock of
PriceSpective LLC (“PriceSpective”), a global leader in
value strategy consulting, for an initial cash consideration of
$40.0 million. Headquartered in Philadelphia, and with
offices in London, Los Angeles, San Diego, Raleigh and Boston,
PriceSpective is a premier consultancy that has a strong reputation
for excellence in strategic pricing, market access, HEOR, due
diligence support and payer engagement services. Since the
company’s inception in 2003, PriceSpective has developed
strategies for dozens of new product launches, and hundreds of
development and in-market products, across 40+ disease areas.
Further consideration of up to $15.0 million may become payable if
certain performance milestones are achieved in the period to
December 2012.
The
following table summarizes the Company’s provisional
estimates of the fair values of assets acquired and the liabilities
assumed:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. No definition available.
|
|
Significant Accounting Policies (Policies)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basis of consolidation | (a) Basis
of consolidation
The
consolidated financial statements include the financial statements
of the Company and all of its subsidiaries. All significant
intercompany profits, transactions and account balances have been
eliminated. The results of subsidiary undertakings acquired in the
period are included in the consolidated statement of operations
from the date of acquisition.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Use of estimates | (b) Use
of estimates
The
preparation of financial statements in conformity with generally
accepted accounting principles in the United States requires
management to make estimates and judgments that affect the reported
amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reported
period. Actual results could differ from those estimates. The
principle management estimates and judgements used in preparing the
financial statements relate to revenue recognition, taxation,
goodwill and business combinations.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue recognition | (c) Revenue
recognition
The
Company primarily earns revenues by providing a number of different
services to its customers. These services, which are integral
elements of the clinical development process, include clinical
trials management, biometric activities, consulting, imaging,
contract staffing, informatics and laboratory services. Contracts
range in duration from a number of months to several
years. Revenue for services, as rendered, is recognized
only after persuasive evidence of an arrangement exists, the sales
price is fixed or determinable and collectability is reasonably
assured.
Clinical
trials management revenue is recognized on a proportional
performance method. Depending on the contractual terms revenue is
either recognized on the percentage of completion method based on
the relationship between hours incurred and the total estimated
hours of the trial or on the unit of delivery method. Contract
costs equate to the product of labor hours incurred and
compensation rates. For the percentage of completion
method, the input (effort expended) method has been used to measure
progress towards completion as there is a direct relationship
between input and productivity. Contract revenue is the product of
the aggregated labor hours required to complete the specified
contract tasks at the agreed contract rates. The Company regularly
reviews the estimate of total contract time to ensure such
estimates remain appropriate taking into account actual contract
stage of completion, remaining time to complete and any identified
changes to the contract scope. Remaining time to complete depends
on the specific contract tasks and the complexity of the contract
and can include geographical site selection and initiation, patient
enrolment, patient testing and level of results analysis required.
While the Company may routinely adjust time estimates, the
Company’s estimates and assumptions historically have been
accurate in all material respects in the
aggregate. Where revenue is recognized on the unit of
delivery method, the basis applied is the number of units completed
as a percentage of the total number of contractual
units.
Biometrics
revenue is recognised on a fee-for-service method as each unit of
data is prepared on the basis of the number of units completed in a
period as a percentage of the total number of contracted
units. Imaging revenue is recognised on a
fee-for-service basis recognizing revenue for each image completed.
Consulting revenue is recognised on a fee-for-service basis as each
hour of the related service is performed. Contract staffing
revenue is recognized on a fee-for-service basis, over the time the
related service is performed, or in the case of permanent
placement, once the candidate has been placed with the
client. Informatics revenue is recognized on a
fee-for-service basis. Informatics contracts are
treated as multiple element arrangements, with contractual elements
comprising licence fee revenue, support fee revenue and revenue
from software services, each of which can be sold separately. Sales
prices for contractual elements are determined by reference to
objective and reliable evidence of their sales price. Licence and
support fee revenues are recognized rateably over the period of the
related agreement. Revenue from software services is
recognized using the percentage of completion method based on the
relationship between hours incurred and the total estimated hours
required to perform the service.
Laboratory
service revenue is recognised on a fee-for-service basis. The
Company accounts for laboratory service contracts as multiple
element arrangements, with contractual elements comprising
laboratory kits and laboratory testing, each of which can be sold
separately. Sales prices for contractual elements are determined by
reference to objective and reliable evidence of their sales price.
Revenues for contractual elements are recognised on the basis of
the number of deliverable units completed in the
period.
Contracts
generally contain provisions for renegotiation in the event of
changes in the scope, nature, duration, or volume of services of
the contract. Renegotiated amounts are recognised as revenue by
revision to the total contract value arising as a result of an
authorised customer change order.
The
difference between the amount of revenue recognised and the amount
billed on a particular contract is included in the balance sheet as
unbilled revenue or payments on account. Normally, amounts become
billable upon the achievement of certain milestones, for example,
target patient enrollment rates, clinical testing sites initiated
or case report forms completed. Once the milestone target is
reached, amounts become billable in accordance with pre-agreed
payment schedules included in the contract or on submission of
appropriate billing detail. Such cash payments are not
representative of revenue earned on the contract as revenues are
recognised over the period in which the specified contractual
obligations are fulfilled. Amounts included in unbilled revenue are
expected to be collected within one year and are included within
current assets. Advance billings to customers, for which revenue
has not been recognised, are recognised as payments on account
within current liabilities.
In
the event of contract termination, if the value of work performed
and recognised as revenue is greater than aggregate milestone
billings at the date of termination, cancellation clauses ensure
that the Company is paid for all work performed to the termination
date.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reimbursable expenses | (d) Reimbursable
expenses
Reimbursable
expenses comprise investigator payments and certain other costs
which are reimbursed by clients under terms specific to each
contract and are deducted from gross revenue in arriving at net
revenue. Investigator payments are accrued based on patient
enrollment over the life of the contract. Investigator payments are
made based on predetermined contractual arrangements, which may
differ from the accrual of the expense. Payments to investigators
in excess of the accrued expense are classified as prepaid expenses
and accrued expense in excess of amounts paid are classified as
accounts payable.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Direct costs | (e) Direct
costs
Direct
costs consist of compensation, associated employee benefits and
share-based payments for project-related employees and other direct
project-related costs.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Advertising costs | (f) Advertising
costs
All
costs associated with advertising and promotion are expensed as
incurred. The advertising and promotion expense was $2,905,000,
$3,431,000 and $2,548,000 for the years ended December 31, 2011,
December 31, 2010 and December 31, 2009 respectively.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currencies and translation of subsidiaries | (g) Foreign
currencies and translation of subsidiaries
The
Company's financial statements are prepared in United States
dollars. Transactions in currencies other than United States
dollars are recorded at the rate ruling at the date of the
transactions. Monetary assets and liabilities denominated in
currencies other than United States dollars are translated into
United States dollars at exchange rates prevailing at the balance
sheet date. Adjustments resulting from these translations are
charged or credited to income. Amounts credited or
charged to the statement of operations for the years ended December
31, 2011, December 31, 2010 and December 31, 2009 were as
follows:
The
financial statements of subsidiaries with other functional
currencies are translated at period end rates for the balance sheet
and average rates for the statement of operations. Translation
gains and losses arising are reported as a movement on accumulated
other comprehensive income.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Disclosure about fair value of financial instruments | (h) Disclosure
about fair value of financial instruments
The
following methods and assumptions were used to estimate the fair
value of each material class of financial instrument:
Cash,
cash equivalents, unbilled revenue, other receivables, short term
investments, prepayments and other current assets, accounts
receivable, accounts payable, investigator payments, payments
received on account, accrued liabilities, accrued bonuses, bank
overdraft and taxes payable have carrying amounts that approximate
fair value due to the short term maturities of these instruments.
Other liabilities’ carrying amounts approximate fair value
based on net present value of estimated future cash
flows.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business combinations | (i) Business
combinations
The cost of a business combination is measured as the aggregate of
the fair values at the date of exchange of assets given,
liabilities incurred or assumed and equity instruments issued in
exchange for control. Where a business combination agreement
provides for an adjustment to the cost of the acquisition which is
contingent upon future events, the amount of the estimated
adjustment is recognised on the acquisition date at the acquisition
date fair value of this contingent consideration. Any changes to
this estimate in subsequent periods will depend on the
classification of the contingent consideration. If the contingent
consideration is classified as equity it shall not be re-measured
and the settlement shall be accounted for within equity. If the
contingent consideration is classified as an asset or liability any
adjustments will be accounted for through the Consolidated
Statement of Operations or other comprehensive income depending on
whether the asset or liability is considered a financial
instrument.
The assets, liabilities and contingent liabilities of businesses
acquired are measured at their fair values at the date of
acquisition. In the case of a business combination which is
completed in stages, the fair values of the identifiable assets,
liabilities and contingent liabilities are determined at the date
of each exchange transaction. When the initial accounting for a
business combination is determined provisionally, any subsequent
adjustments to the provisional values allocated to the identifiable
assets, liabilities and contingent liabilities are made within
twelve months of the acquisition date and presented as adjustments
to the original acquisition accounting.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill and Impairment | (j) Goodwill
and Impairment
Goodwill
represents the excess of the cost of acquired entities over the net
amounts assigned to assets acquired and liabilities assumed.
Goodwill primarily comprises acquired workforce in place which does
not qualify for recognition as an asset apart from
goodwill. Goodwill is stated net of any provision for
impairment. The Company tests goodwill annually for any impairments
or whenever events occur which may indicate impairment. The first
step is to compare the carrying amount of the reporting
unit’s assets to the fair value of the reporting unit. If the
carrying amount exceeds the fair value then a second step is
completed which involves the fair value of the reporting unit being
allocated to each asset and liability with the excess being implied
goodwill. The impairment loss is the amount by which the recorded
goodwill exceeds the implied goodwill. No impairment was recognized
as a result of the impairment testing carried out for the years
ended December 31, 2011, December 31, 2010 and December 31,
2009.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible assets | (k) Intangible
assets
Intangible
assets are amortized on a straight line basis over their estimated
useful life.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash and cash equivalents | (l) Cash
and cash equivalents
Cash
and cash equivalents include cash and highly liquid investments
with initial maturities of three months or less and are stated at
cost, which approximates market value.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Short term investments - available for sale | (m) Short
term investments - available for sale
The
Company classifies short-term investments as available for sale in
accordance with the terms of FASB ASC 320, Investments – Debt and
Equity Securities. Realized gains and losses are
determined using specific identification. The
investments are reported at fair value, with unrealized gains or
losses reported in a separate component of shareholders’
equity. Any differences between the cost and fair value
of the investments are represented by accrued
interest.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | (n) Inventory
Inventory
is valued at the lower of cost and net market value and after
provisions for obsolescence. Cost of raw materials comprises the
purchase price and attributable costs, less trade
discounts. At December 31, 2011 the carrying value of
inventory, included within prepayments and other current assets on
the balance sheet, was $2.8 million (2010: $3.8
million).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, plant and equipment | (o) Property,
plant and equipment
Property,
plant and equipment is stated at cost less accumulated
depreciation. Depreciation of property, plant and equipment is
computed using the straight line method based on the estimated
useful lives of the assets as listed below:
Leasehold
improvements are amortized using the straight-line method over the
estimated useful life of the asset or the lease term, whichever is
shorter.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Leased assets | (p) Leased
assets
Costs
in respect of operating leases are charged to the statement of
operations on a straight line basis over the lease
term.
Assets
acquired under capital finance leases are included in the balance
sheet at the present value of the future minimum lease payments and
are depreciated over the shorter of the lease term and their
remaining useful lives. The corresponding liabilities are recorded
in the balance sheet and the interest element of the capital lease
rental is charged to interest expense.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Income taxes | (q) Income
taxes
The
Company applies FASB ASC 740, Income Taxes
(“ASC 740”), which requires the asset and liability
method of accounting for income taxes. Under the asset and
liability method of ASC 740, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to
differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases, and
operating loss and tax credit carryforwards. Deferred tax assets
and liabilities are measured using enacted tax rates expected to
apply to taxable income in the years in which these temporary
differences are expected to be recovered or settled. The effect on
deferred tax assets and liabilities of a change in tax rates is
recognized in income in the period that includes the enactment
date. ASC 740 requires that the Company recognizes the
largest amount of tax benefit that is greater than 50% likely of
being realized upon effective settlement when considering uncertain
tax positions.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Government grants | (r) Government
grants
Government
grants received relating to capital expenditure are shown as
deferred income and credited to income on a basis consistent with
the depreciation policy of the relevant assets. Grants
relating to categories of operating expenditures are credited to
income in the period in which the expenditure to which they relate
is charged.
Under
the grant agreements amounts received may become repayable in full
should certain circumstances specified within the grant agreements
occur, including downsizing by the Company, disposing of the
related assets, ceasing to carry on its business or the appointment
of a receiver over any of its assets. The Company has
not recognized any loss contingency having assessed as remote the
likelihood of these events arising.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Research and development credits | (s) Research
and development credits
Research
and development credits are available to the Company under the tax
laws in certain jurisdictions, based on qualifying research and
development spend as defined under those tax laws. Research and
development credits are generally recognized as a reduction of
income tax expense. However, certain tax jurisdictions provide
refundable credits that are not wholly dependent on the
Company’s ongoing income tax status or income tax position.
In these circumstances the benefit of these credits is not recorded
as a reduction to income tax expense, but rather as a reduction of
the operating expenditure to which the credits relate.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pension costs | (t) Pension
costs
The
Company contributes to defined contribution plans covering all
eligible employees. The Company contributes to these plans based
upon various fixed percentages of employee compensation and such
contributions are expensed as incurred.
The
Company operates, through a subsidiary, a defined benefit plan for
certain of its United Kingdom employees. The Company accounts for
the costs of this plan using actuarial models required by FASB ASC
715-30 and the plan is presented in accordance with the
requirements of FASB ASC 715-60 Defined Benefit Plans –
Other Postretirement.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income per ordinary share | (u) Net
income per ordinary share
Basic
net income per ordinary share has been computed by dividing net
income available to ordinary shareholders by the weighted average
number of ordinary shares outstanding during the period. Diluted
net income per ordinary share is computed by adjusting the weighted
average number of ordinary shares outstanding during the period for
all potentially dilutive ordinary shares outstanding during the
period and adjusting net income for any changes in income or loss
that would result from the conversion of such potential ordinary
shares.
There
is no difference in net income used for basic and diluted net
income per ordinary share. The reconciliation of the number of
shares used in the computation of basic and diluted net income per
ordinary share is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | (v) Share-based
compensation
The
Company accounts for its share options in accordance with the
provisions of FASB ASC 718, Compensation – Stock
Compensation. Share-based compensation expense for
equity-settled awards made to employees and directors is measured
and recognized based on estimated grant date fair values. These
awards include employee stock options.
Share-based
compensation expense for stock options awarded to employees and
directors is estimated at the grant date based on each
option’s fair value as calculated using the Black-Scholes
option-pricing model. The value of awards expected to vest is
recognized as an expense over the requisite service
periods.
Estimating
the fair value of share-based awards as of the grant date using an
option-pricing model, such as the Black-Scholes model, is affected
by the Company’s share price as well as assumptions regarding
a number of complex variables. These variables include, but are not
limited to, the expected share price volatility over the term of
the awards, risk-free interest rates, and the expected term of the
awards.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Impairment of long-lived assets | (w) Impairment
of long-lived assets
Long
lived assets are reviewed for impairment whenever events or changes
in circumstances indicate that the carrying amount of an asset may
not be recoverable. Recoverability of assets to be held and used is
measured by a comparison of the carrying amount of an asset to
future undiscounted net cash flows expected to be generated by the
asset. If such assets are considered to be impaired, the impairment
to be recognized is measured by the amount by which the carrying
amount of the assets exceeds the fair value of the assets. Assets
to be disposed of are reported at the lower of the carrying amount
or fair value less selling costs.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reclassifications | (x) Reclassifications
Certain
amounts in the consolidated financial statements have been
reclassified where necessary to conform to the current year
presentation.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Government Grants, Policy No definition available.
|
| X | ||||||||||
|
- Definition
Reclassifications Policy No definition available.
|
| X | ||||||||||
|
- Definition
Reimbursable expenses No definition available.
|
| X | ||||||||||
|
- Definition
Short Term Investments , Policy No definition available.
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for determining the fair value of financial instruments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Significant Accounting Policies (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Adjustments Resulting From Foreign Currency Translations | Amounts
credited or charged to the statement of operations for the years
ended December 31, 2011, December 31, 2010 and December 31, 2009
were as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Estimated Useful Lives Of Assets | Property,
plant and equipment is stated at cost less accumulated
depreciation. Depreciation of property, plant and equipment is
computed using the straight line method based on the estimated
useful lives of the assets as listed below:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share | The
reconciliation of the number of shares used in the computation of
basic and diluted net income per ordinary share is as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Foreign Currency Disclosure No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Useful Lives For Property Plant Equipment No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations. No definition available.
|
|
Short term investments - available for sale (Tables)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cost and fair value of the investments |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. No definition available.
|
|
Goodwill (Tables)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Firecrest Clinical Limited
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Assets Acquired and Liabilities Assumed | The
following table summarizes the estimated fair values of the assets
acquired and the liabilities assumed:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Proforma Effect in Net Revenue Net Income and Earnings Per Share | The
proforma effect of the Firecrest acquisition if completed on
January 1, 2010 would have resulted in net revenue, net income and
earnings per share for the fiscal years ended December 31, 2010 and
December 31, 2011 as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Oxford Outcomes Limited
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Assets Acquired and Liabilities Assumed | The
following table summarizes the estimated fair values of the assets
acquired and the liabilities assumed:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Proforma Effect in Net Revenue Net Income and Earnings Per Share | The
proforma effect of the Oxford Outcomes acquisition if completed on
January 1, 2010 would have resulted in net revenue, net income and
earnings per share for the fiscal years ended December 31, 2010 and
December 31, 2011 as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Timaq Medical Imaging
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Assets Acquired and Liabilities Assumed | The
following table summarizes the fair values of the assets acquired
and the liabilities assumed:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Proforma Effect in Net Revenue Net Income and Earnings Per Share | The
proforma effect of the Timaq Medical Imaging acquisition if
completed on January 1, 2009 would have resulted in net revenue,
net income and earnings per share for the fiscal years ended
December 31, 2009 and December 31, 2010 as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Healthcare Discoveries Inc
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Assets Acquired and Liabilities Assumed | The
following table summarizes the fair values of the assets acquired
and the liabilities assumed at the date of
acquisition.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of goodwill by reportable segment and in total. Disclosure details may include, but are not limited to, the carrying amount of goodwill, goodwill acquired during the year, goodwill impairment losses recognized, goodwill written-off due to the sale of a business unit, goodwill not yet allocated, and any other changes to goodwill. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Intangible Assets (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible Assets |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Future Intangible Asset Amortization Expense | Future
intangible asset amortization expense for the years ended December
31, 2012 to December 31, 2016 is as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of amortizable intangibles assets, in total and by major class, including the gross carrying amount and accumulated amortization. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. No definition available.
|
|
Property, Plant and Equipment, net (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property Plant and Equipment Net |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Other Liabilities (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Other Liabilities Table Disclosure No definition available.
|
|
Other Non-Current Liabilities (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Noncurrent Liabilities |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Other Noncurrent Liabilities, Table No definition available.
|
|
Employee Benefits (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pension Costs of the Plan | The
pension costs of this plan are presented in the following tables in
accordance with the requirements of ASC 715-60, Defined Benefit Plans –
Other Postretirement. The plan has been closed to new
entrants with effect from July 1, 2003.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Funded Status |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Components of Net Periodic Benefit Cost/(Credit) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Amounts Recognized In Accumulated Other Comprehensive Income That Has Not Yet Been Recognized As Components Of Net Periodic Benefit Cost | Amounts
recognized in accumulated other comprehensive income that has not
yet been recognized as components of net periodic benefit cost are
as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Expected Long Term Rates of Return on Different Asset Classes | The
expected long term rates of return on different asset classes over
the long term are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Plan Asset Fair Value Measurements | The
underlying asset split of the fund is shown below.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Annual Benefit Payments which Reflect Expected Future Service | The
following annual benefit payments, which reflect expected future
service, as appropriate, are expected to be paid.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Fair Value, Inputs, Level 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Plan Asset Fair Value Measurements |
Plan Asset Fair Value Measurements
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Pension Plans, Defined Benefit
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assumptions Used | The
following assumptions were used at the commencement of the year in
determining the net periodic pension benefit cost/(credit) for the
years ended December 31, 2009, December 31, 2010 and December 31,
2011:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Benefit Obligations
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assumptions Used | The
following assumptions were used in determining the benefit
obligation at December 31, 2011:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Expected Long Term Rate of Return on Plan Assets No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation and net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of net funded status of pension plans and/or other employee benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Share Options and Stock Compensation Charges (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transactions for Company's Share Option Plans | The
following table summarizes the transactions for the Company’s
share option plans for the years ended December 31, 2011, December
31, 2010 and December 31, 2009:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non Vested Shares Outstanding | Non
vested shares outstanding as at December 31, 2011 are as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Information Concerning Outstanding and Exercisable Share Options | The
following table summarizes information concerning outstanding and
exercisable share options as of December 31, 2011:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Weighted Average Fair Values and Assumptions Used | The
weighted average fair values and assumptions were as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RSU Granted During Period | The
Company has awarded restricted Share Units
(“RSU’s”) to certain key executives of the
Group. Details of RSU’s granted during the year
ended December 31, 2011 were as follows:
*
includes 100,000 RSU’s awarded to Mr. Peter Gray which are
not expected to vest following his retirement as CEO of the Company
on September 30, 2011.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Movement in Non-vested RSU's | The
following table summarizes the movement in non-vested RSU’s
during the year ended December 31, 2011:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Non-cash Stock Compensation Expense | Non-cash
stock compensation expense for the year ended December 31, 2011 has
been allocated to direct costs and selling, general and
administrative expenses as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Schedule of Non Cash Stock Compensation Expense No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the changes in outstanding nonvested restricted stock units. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the changes in outstanding nonvested shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Government Grants (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Government Grant |
11. Government Grants
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Government Grants No definition available.
|
|
Income Taxes (Tables)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Components of Income Before Provision for Income Tax Expense | The
components of income before provision for income tax expense are as
follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Components of Total Income Tax Expense | The
components of total income tax expense are as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reconciliation of Consolidated Effective Tax Rate and Statutory Rate | The
Company’s consolidated effective tax rate differed from the
statutory rate as set forth below;
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Tax Assets and Deferred Tax Liabilities | The
tax effects of temporary differences that give rise to significant
portions of deferred tax assets and deferred tax liabilities are
presented below:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reconciliation of Beginning and Ending Amount of Total Unrecognized Tax Benefits | A
reconciliation of the beginning and ending amount of total
unrecognized tax benefits is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Central Laboratory
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Expected Expiry Dates of NOL's | The
expected expiry dates of these losses are as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Clinical Research
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Expected Expiry Dates of NOL's | The
expected expiry dates of these losses are as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Oxford Outcomes Limited
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Expected Expiry Dates of NOL's | The
expected expiry dates of these losses are as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Income Before Income Tax, Table No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of income tax contingencies, including: (1) the policy on classification of interest and penalties; (2) a tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period; the total amount(s) of: (3) unrecognized tax benefits that, if recognized, would affect the effective tax rate, and (4) interest and penalties recognized in each of the income statement and balance sheet; (5) for positions for which it is reasonably possible that the total amounts unrecognized will significantly change within 12 months of the reporting date the: (i) nature of the uncertainty, (ii) nature of the event that could occur that would cause the change, and (iii) an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made; and (6) a description of tax years that remain subject to examination by major tax jurisdictions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Non-recurring charges, net (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-recurring charges, net | Non-recurring
charges, net recognized during the year ended December 31, 2011
comprise:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Details of Restructuring Provisions Recognized | Details
of the movement in the 2011 Restructuring Plan recognized during
the year ended December 31, 2011 is as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Details of Movement in Restructuring Provisions Recognised | Details
of movement in the 2009 Restructuring Plan recognized during the
years ended December 31, 2009 to December 2011 is as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Restructuring, and Research and Development [Table Text Block] No definition available.
|
| X | ||||||||||
|
- Definition
Restructuring, Closures and Asset Impairments No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Significant Concentrations (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Provision for doubtful debts | The
Company does business with most major international pharmaceutical
companies. Provision for doubtful debts at December 31, 2011
comprises:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Allowance for Doubtful Accounts, Table No definition available.
|
|
Commitments and Contingencies (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Future Minimum Rental Commitments for Operating Leases with Non-cancelable Terms | Future minimum rental commitments for
operating leases with non-cancelable terms in excess of one year
are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Business Segment Information (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Net Revenue by Geographical Area | a) The
distribution of net revenue by geographical area was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Net Revenue by Business Segment |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Income from Operations by Geographical Area |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Income from Operations by Business Segment |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Property, Plant and Equipment, Net, by Geographical Area |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Property, Plant and Equipment, Net, by Business Segment |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Depreciation and Amortization by Geographical Area | g) The
distribution of depreciation and amortization by geographical area
was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Depreciation and Amortization by Business Segment | h) The
distribution of depreciation and amortization by business segment
was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Total Assets by Geographical Area | i) The
distribution of total assets by geographical area was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Total Assets by Business Segment | j)
The distribution of total assets by business segment was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Capital Expenditures by Geographical Area | k)
The distribution of capital expenditures by geographical area was
as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Capital Expenditures by Business Segment | l)
The distribution of capital expenditures by business segment was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clients Representing Company's Net Revenue | m)
The following table sets forth the clients which represented 10% or
more of the Company's net revenue in each of the periods set out
below.
*
Net revenue did not exceed 10%.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Interest Income by Geographical Area | n)
The distribution of interest income by geographical area was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Interest Income by Business Segment | o)
The distribution of interest income by business segment was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Tax Charge by Geographical Area | p)
The distribution of the tax charge by geographical area was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Distribution of Tax Charge by Business Segment | q)
The distribution of the tax charge by business segment was as
follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Net Revenue by Business Segment No definition available.
|
| X | ||||||||||
|
- Definition
Operating Income by Geography No definition available.
|
| X | ||||||||||
|
- Definition
Operating Income by Segment No definition available.
|
| X | ||||||||||
|
- Definition
Property, Plant and Equipment by Geography No definition available.
|
| X | ||||||||||
|
- Definition
Revenues by Geography No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Capital Expenditures by Geographic Area No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Capital Expenditures by Segment No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Depreciation And Amortization Expense By Geographical Area No definition available.
|
| X | ||||||||||
|
- Definition
Schedule of Depreciation and Amortization Expense by Segment No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Income Tax Expense Benefit by Geographic Area No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Income Tax Expense Benefit by Segment No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Interest Incom by Segment No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Interest Income by Geographic Area No definition available.
|
| X | ||||||||||
|
- Definition
Schedule of Property, Plant and Equipment, Net by Segment No definition available.
|
| X | ||||||||||
|
- Definition
Schedule Of Total Assets By Geographic Area No definition available.
|
| X | ||||||||||
|
- Definition
Schedule of Total Assets by Segment No definition available.
|
| X | ||||||||||
|
- Definition
Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Supplemental Disclosure of Cash Flow Information (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Supplemental Disclosure of Cash Flow Information |
*
recorded within interest expense
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of supplemental cash flow information for the periods presented. No definition available.
|
|
Accumulated Other Comprehensive Income (Tables)
|
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accumulated Other Comprehensive Income |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Tabular disclosure of the components of accumulated other comprehensive income (loss). No definition available.
|
|
Subsequent Events (Tables)
|
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Provisional Estimates of Fair Values of Assets Acquired and Liabilities Assumed |
Acquisition of BeijingWits Medical Limited
The
following table summarizes the Company’s provisional
estimates of the fair values of assets acquired and the liabilities
assumed:
Acquisition of PriceSpective LLC
The
following table summarizes the Company’s provisional
estimates of the fair values of assets acquired and the liabilities
assumed:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
|
- Definition
Preliminary Fair Values of Assets Acquired and Liabilities Assumed Related to Acquisition No definition available.
|
|
Description Of Business - Additional Information (Detail)
|
12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
Location
Employee
Country
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|||||
| Product Information [Line Items] | |||||||
| Number of employees | 8,470 | ||||||
| Number of locations in which company operates | 81 | ||||||
| Number of countries in which company operates | 40 | ||||||
| Percentage of company revenue | 13.00% | [1] | [1] | ||||
|
U.S.
|
|||||||
| Product Information [Line Items] | |||||||
| Percentage of company revenue | 41.70% | ||||||
|
Europe
|
|||||||
| Product Information [Line Items] | |||||||
| Percentage of company revenue | 46.20% | ||||||
|
Rest of World
|
|||||||
| Product Information [Line Items] | |||||||
| Percentage of company revenue | 12.10% | ||||||
|
|||||||
| X | ||||||||||
|
- Definition
Number of persons employed by the Entity No definition available.
|
| X | ||||||||||
|
- Definition
Number of Locations No definition available.
|
| X | ||||||||||
|
- Definition
Percentage of Company Revenue No definition available.
|
| X | ||||||||||
|
- Definition
The number of countries in which the entity operates as of balance sheet date. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Significant Accounting Policies - Additional Information (Detail) (USD $)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Significant Accounting Policies [Line Items] | |||
| Advertising and promotion expense | $ 2,905,000 | $ 3,431,000 | $ 2,548,000 |
| Impairment charge | 0 | 0 | 0 |
| Carrying Value Of Inventory | $ 2,800,000 | $ 3,800,000 | |
| Amount of tax benefit likely of being realized upon effective settlement | 50.00% | ||
| X | ||||||||||
|
- Definition
Income Tax Examination Minimum Likelihood of Tax Benefits Being Realized Upon Ultimate Settlement No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total expense recognized in the period for promotion, public relations, and brand or product advertising. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Adjustments Resulting From Foreign Currency Translations (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Intercompany Foreign Currency Balance [Line Items] | |||
| Amounts charged | $ 391 | $ 3,731 | $ 1,639 |
| X | ||||||||||
|
- Definition
The aggregate foreign currency transaction gain (loss) (both realized and unrealized) included in determining net income for the reporting period. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements. For certain enterprises, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Estimated Useful Lives Of Assets (Detail)
|
12 Months Ended |
|---|---|
|
Dec. 31, 2011
Year
|
|
|
Buildings
|
|
| Property, Plant and Equipment [Line Items] | |
| Estimated useful lives, maximum | 40 |
|
Office furniture and fixtures
|
|
| Property, Plant and Equipment [Line Items] | |
| Estimated useful lives, maximum | 8 |
|
Laboratory equipment
|
|
| Property, Plant and Equipment [Line Items] | |
| Estimated useful lives, maximum | 5 |
|
Motor vehicles
|
|
| Property, Plant and Equipment [Line Items] | |
| Estimated useful lives, maximum | 5 |
|
Computer equipment and software
|
|
| Property, Plant and Equipment [Line Items] | |
| Estimated useful lives, minimum | 4 |
| Estimated useful lives, maximum | 8 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. No definition available.
|
| X | ||||||||||
|
- Definition
The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. No definition available.
|
|
Reconciliation of Number of Shares Used in the Computation of Basic and Diluted Net Income Per Ordinary Share (Detail)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Schedule of Weighted Average Number of Diluted Shares Outstanding [Line Items] | |||
| Weighted average number of ordinary shares outstanding for basic net income per ordinary share | 60,379,338 | 59,718,934 | 58,636,878 |
| Effect of dilutive share options outstanding | 691,348 | 918,169 | 1,263,626 |
| Weighted average number of ordinary shares for diluted net income per ordinary share | 61,070,686 | 60,637,103 | 59,900,504 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Cost and Fair Value of Investments (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Schedule of Available-for-sale Securities [Line Items] | ||
| At start of period/year | $ 49,227 | |
| Additions | 56,000 | 30,260 |
| Disposals | (438) | (79,487) |
| Unrealized capital gain/(loss) - investments | (622) | |
| At end of period/year | $ 54,940 | |
| X | ||||||||||
|
- Definition
Available For Sale Securities, Debt Securities Current, Additions No definition available.
|
| X | ||||||||||
|
- Definition
Available For Sale Securities, Debt Securities Current, Disposals No definition available.
|
| X | ||||||||||
|
- Definition
Available For Sale Securities, Unrealized Gain (Loss) No definition available.
|
| X | ||||||||||
|
- Definition
Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature within one year from the balance sheet date or the normal operating cycle, whichever is longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Goodwill (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Goodwill [Line Items] | ||
| Opening goodwill | $ 175,860 | $ 173,568 |
| Current period acquisitions | 83,656 | 3,505 |
| Prior period acquisitions | 2,539 | |
| Foreign exchange movement | (6,123) | (3,752) |
| Closing goodwill | $ 253,393 | $ 175,860 |
| X | ||||||||||
|
- Definition
Goodwill Acquired Prior Period No definition available.
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of goodwill acquired in the period and allocated to the reportable segment. The value is stated at fair value based on the purchase price allocation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The increase (decrease) to the recorded value of goodwill for foreign currency translation adjustments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Goodwill - Additional Information (Detail)
In Millions, unless otherwise specified |
Dec. 31, 2011
Timaq Medical Imaging
USD ($)
|
Dec. 31, 2011
Timaq Medical Imaging
CHF
|
Nov. 05, 2010
Timaq Medical Imaging
USD ($)
|
Nov. 05, 2010
Timaq Medical Imaging
CHF
|
May 17, 2010
Timaq Medical Imaging
USD ($)
|
May 17, 2010
Timaq Medical Imaging
CHF
|
Nov. 05, 2010
Timaq Medical Imaging
Maximum
CHF
|
May 17, 2010
Timaq Medical Imaging
Maximum
USD ($)
|
May 17, 2010
Timaq Medical Imaging
Maximum
CHF
|
Dec. 31, 2011
Firecrest Clinical Limited
USD ($)
|
Dec. 31, 2011
Firecrest Clinical Limited
EUR (€)
|
Jul. 14, 2011
Firecrest Clinical Limited
USD ($)
|
Jul. 14, 2011
Firecrest Clinical Limited
EUR (€)
|
Jul. 14, 2011
Firecrest Clinical Limited
Maximum
USD ($)
|
Jul. 14, 2011
Firecrest Clinical Limited
Maximum
EUR (€)
|
Dec. 31, 2011
Oxford Outcomes Limited
USD ($)
|
Dec. 31, 2011
Oxford Outcomes Limited
GBP (£)
|
Jul. 31, 2011
Oxford Outcomes Limited
USD ($)
|
Jul. 31, 2011
Oxford Outcomes Limited
GBP (£)
|
May 31, 2011
Oxford Outcomes Limited
USD ($)
|
May 31, 2011
Oxford Outcomes Limited
GBP (£)
|
Jan. 14, 2011
Oxford Outcomes Limited
USD ($)
|
Jan. 14, 2011
Oxford Outcomes Limited
GBP (£)
|
Jan. 14, 2011
Oxford Outcomes Limited
Maximum
USD ($)
|
Jan. 14, 2011
Oxford Outcomes Limited
Maximum
GBP (£)
|
Dec. 31, 2011
Oxford Outcomes Limited
Put and call option
USD ($)
|
Dec. 31, 2011
Oxford Outcomes Limited
Put and call option
GBP (£)
|
Oct. 20, 2011
Oxford Outcomes Limited
Put and call option
USD ($)
|
Oct. 20, 2011
Oxford Outcomes Limited
Put and call option
GBP (£)
|
Jan. 14, 2011
Oxford Outcomes Limited
Put and call option
USD ($)
|
Jan. 14, 2011
Oxford Outcomes Limited
Put and call option
GBP (£)
|
Jan. 14, 2011
Oxford Outcomes Limited
Put and call option
Maximum
USD ($)
|
Jan. 14, 2011
Oxford Outcomes Limited
Put and call option
Maximum
GBP (£)
|
Sep. 03, 2010
Healthcare Discoveries Inc
USD ($)
|
Feb. 11, 2008
Healthcare Discoveries Inc
USD ($)
|
Dec. 31, 2008
Healthcare Discoveries Inc
Maximum
USD ($)
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goodwill [Line Items] | ||||||||||||||||||||||||||||||||||||
| Cash consideration | $ 1.2 | 1.3 | $ 24.1 | € 17.0 | $ 27.6 | £ 17.8 | $ 6.0 | £ 3.8 | $ 11.1 | |||||||||||||||||||||||||||
| First element of additional consideration paid | 0.6 | 0.6 | 5.1 | 3.3 | 2.2 | |||||||||||||||||||||||||||||||
| Percentage of common stock acquired | 100.00% | 100.00% | 80.00% | 80.00% | 100.00% | |||||||||||||||||||||||||||||||
| Potential additional consideration | 0.3 | 0.3 | 2.0 | 2.6 | 2.9 | 46.8 | 33.0 | 1.2 | 0.8 | 10.1 | 6.5 | 2.3 | 1.5 | 10.0 | ||||||||||||||||||||||
| Deferred payments to selling shareholders | 0.3 | 0.3 | ||||||||||||||||||||||||||||||||||
| Cash paid | 6.0 | 3.8 | ||||||||||||||||||||||||||||||||||
| Accrual in respect performance milestones | 2.6 | 2.9 | 40.6 | 31.3 | 4.9 | 3.2 | 1.2 | 0.8 | ||||||||||||||||||||||||||||
| Additional amount Company paid on completion of review | 5.1 | 3.3 | ||||||||||||||||||||||||||||||||||
| Amounts due in respect of the performance milestones to the selling shareholders | 1.1 | 0.7 | ||||||||||||||||||||||||||||||||||
| Accrual amount released in respect to performance milestones | $ 1.7 | 2.0 |
| X | ||||||||||
|
- Definition
Business Acquisition, Accrued Consideration Payable No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition Contingent And Deferred Consideration No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Cost of Acquired Entity, Additional Cash Paid No definition available.
|
| X | ||||||||||
|
- Definition
Amount of cash paid in respect to performance milestones. No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Cost of Acquired Entity, Consideration Paid No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Cost of Acquired Entity, Released from Liabilities No definition available.
|
| X | ||||||||||
|
- Definition
Amount of potential cash payments that could result from the contingent consideration arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of cash paid to acquire the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total cost of the acquired entity including the cash paid to shareholders of acquired entities, fair value of debt and equity securities issued to shareholders of acquired entities, the fair value of the liabilities assumed, and direct costs of the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Percentage of voting equity interests acquired in the business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Summary of Fair Values of the Assets Acquired and the Liabilities Assumed Related to Acquisition of Firecrest (Detail) (Firecrest Clinical Limited, USD $)
In Thousands, unless otherwise specified |
Jul. 14, 2011
|
|---|---|
| Business Acquisition [Line Items] | |
| Property, plant and equipment | $ 687 |
| Goodwill | 48,073 |
| Cash and cash equivalents | 1,965 |
| Other current assets | 3,713 |
| Deferred tax liability | (2,367) |
| Other liabilities | (2,521) |
| Purchase price | 68,491 |
|
Technology Assets
|
|
| Business Acquisition [Line Items] | |
| Intangible asset | 11,169 |
|
Customer relationships acquired
|
|
| Business Acquisition [Line Items] | |
| Intangible asset | 5,243 |
|
Order Backlog
|
|
| Business Acquisition [Line Items] | |
| Intangible asset | 1,172 |
|
Trade Names
|
|
| Business Acquisition [Line Items] | |
| Intangible asset | $ 1,357 |
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Deferred Income Tax Liabilities No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Other Current Assets No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Other Liabilities No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will be amortized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total purchase price of the acquired entity. This includes cash paid to equity interest holders of the acquired entity, fair value of debt and equity securities issued to equity holders of the acquired entity, and transaction costs paid to third parties to consummate the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash and cash equivalents acquired in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of goodwill arising from a business combination, which is the excess of the cost of the acquired entity over the amounts assigned to assets acquired and liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to property, plant and equipment to be used in ongoing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Proforma Effect in Net Revenue, Net Income and Earnings Per Share (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified |
12 Months Ended | |||||
|---|---|---|---|---|---|---|
|
Dec. 31, 2011
Firecrest Clinical Limited
|
Dec. 31, 2010
Firecrest Clinical Limited
|
Dec. 31, 2011
Oxford Outcomes Limited
|
Dec. 31, 2010
Oxford Outcomes Limited
|
Dec. 31, 2010
Timaq Medical Imaging
|
Dec. 31, 2009
Timaq Medical Imaging
|
|
| Business Acquisition [Line Items] | ||||||
| Net revenue | $ 952,729 | $ 906,311 | $ 945,729 | $ 919,524 | $ 900,370 | $ 888,929 |
| Net income | $ 25,851 | $ 86,127 | $ 22,880 | $ 91,524 | $ 86,594 | $ 93,332 |
| Basic earnings per share | $ 0.43 | $ 1.44 | $ 0.38 | $ 1.53 | $ 1.45 | $ 1.59 |
| Diluted earnings per share | $ 0.42 | $ 1.42 | $ 0.37 | $ 1.51 | $ 1.43 | $ 1.56 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of Fair Values of the Assets Acquired and the Liabilities Assumed Related to Acquisition of Oxford Outcomes (Detail) (Oxford Outcomes Limited, USD $)
In Thousands, unless otherwise specified |
Jan. 14, 2011
|
|---|---|
| Business Acquisition [Line Items] | |
| Property, plant and equipment | $ 490 |
| Goodwill | 35,583 |
| Cash and cash equivalents | 6,335 |
| Other current assets | 6,792 |
| Deferred tax liability | (2,003) |
| Other liabilities | (2,128) |
| Purchase price | 52,335 |
|
Customer relationships acquired
|
|
| Business Acquisition [Line Items] | |
| Intangible asset | 6,648 |
|
Order Backlog
|
|
| Business Acquisition [Line Items] | |
| Intangible asset | $ 618 |
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Deferred Income Tax Liabilities No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Other Current Assets No definition available.
|
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Other Liabilities No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will be amortized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total purchase price of the acquired entity. This includes cash paid to equity interest holders of the acquired entity, fair value of debt and equity securities issued to equity holders of the acquired entity, and transaction costs paid to third parties to consummate the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash and cash equivalents acquired in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of goodwill arising from a business combination, which is the excess of the cost of the acquired entity over the amounts assigned to assets acquired and liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to property, plant and equipment to be used in ongoing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of Fair Values of the Assets Acquired and the Liabilities Assumed Related to Acquisition of Timaq Medical Imaging (Detail) (Timaq Medical Imaging, USD $)
In Thousands, unless otherwise specified |
May 17, 2010
|
|---|---|
|
Timaq Medical Imaging
|
|
| Business Acquisition [Line Items] | |
| Property, plant and equipment | $ 107 |
| Goodwill | 3,505 |
| Intangible assets | 770 |
| Other current assets | 160 |
| Current liabilities | (719) |
| Purchase price | $ 3,823 |
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Other Current Assets No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will be amortized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total purchase price of the acquired entity. This includes cash paid to equity interest holders of the acquired entity, fair value of debt and equity securities issued to equity holders of the acquired entity, and transaction costs paid to third parties to consummate the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to current liabilities of the acquired entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of goodwill arising from a business combination, which is the excess of the cost of the acquired entity over the amounts assigned to assets acquired and liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to property, plant and equipment to be used in ongoing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of Fair Values of the Assets Acquired and the Liabilities Assumed Related to Acquisition of Healthcare Discoveries Inc (Detail) (Healthcare Discoveries Inc, USD $)
In Thousands, unless otherwise specified |
Feb. 11, 2008
|
|---|---|
|
Healthcare Discoveries Inc
|
|
| Business Acquisition [Line Items] | |
| Property, plant and equipment | $ 327 |
| Intangible assets | 2,890 |
| Goodwill | 12,424 |
| Cash and cash equivalents | 5 |
| Other current assets | 575 |
| Current liabilities | (1,951) |
| Purchase price | $ 14,270 |
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Other Current Assets No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will be amortized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total purchase price of the acquired entity. This includes cash paid to equity interest holders of the acquired entity, fair value of debt and equity securities issued to equity holders of the acquired entity, and transaction costs paid to third parties to consummate the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash and cash equivalents acquired in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to current liabilities of the acquired entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of goodwill arising from a business combination, which is the excess of the cost of the acquired entity over the amounts assigned to assets acquired and liabilities assumed. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to property, plant and equipment to be used in ongoing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Intangible Assets (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Cost | ||
| Foreign exchange movement | $ (1,728) | $ (55) |
| Intangible assets gross | 37,576 | 15,077 |
| Accumulated amortization | (9,467) | (6,933) |
| Foreign exchange movement | 151 | 134 |
| Net book value | 28,260 | 8,278 |
|
Customer relationships acquired
|
||
| Cost | ||
| Intangible assets gross | 22,193 | 12,337 |
|
Technology Assets
|
||
| Cost | ||
| Intangible assets gross | 11,169 | |
|
Order Backlog
|
||
| Cost | ||
| Intangible assets gross | 3,260 | 1,470 |
|
Trade Names
|
||
| Cost | ||
| Intangible assets gross | 1,357 | |
|
Volunteer list acquired
|
||
| Cost | ||
| Intangible assets gross | $ 1,325 | $ 1,325 |
| X | ||||||||||
|
- Definition
Finite Lived Intangible Assets Accumulated Amortizations Foreign Exchange Movement No definition available.
|
| X | ||||||||||
|
- Definition
Finite Lived Intangible Assets Foreign Exchange Movement No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The accumulated amount of amortization of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of the gross carrying amounts before accumulated amortization as of the balance sheet date of all intangible assets having statutory or estimated useful lives. The aggregate gross carrying amount (including any previously recognized impairment charges) of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate sum of gross carrying value of a major finite-lived intangible asset class, less accumulated amortization and any impairment charges. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Intangible Assets - Additional Information (Detail) (USD $)
|
6 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 19 Months Ended | 1 Months Ended | 36 Months Ended | 12 Months Ended | 36 Months Ended | 1 Months Ended | 38 Months Ended | 1 Months Ended | 47 Months Ended | 1 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
Firecrest Clinical Limited
|
Jul. 14, 2011
Firecrest Clinical Limited
|
Jul. 14, 2011
Firecrest Clinical Limited
Customer relationships acquired
Year
|
Jul. 14, 2011
Firecrest Clinical Limited
Order Backlog
Year
|
Jul. 14, 2011
Firecrest Clinical Limited
Technology Assets
Year
|
Jul. 14, 2011
Firecrest Clinical Limited
Trade Names
Year
|
Dec. 31, 2011
Oxford Outcomes Limited
|
Jan. 14, 2011
Oxford Outcomes Limited
|
Jan. 14, 2011
Oxford Outcomes Limited
Customer relationships acquired
Year
|
Jan. 14, 2011
Oxford Outcomes Limited
Order Backlog
Year
|
Dec. 31, 2011
Timaq Medical Imaging
|
May 17, 2010
Timaq Medical Imaging
Customer relationships acquired
Year
|
Dec. 31, 2011
Qualia Clinical Services, Inc, and Veeda Laboratories Limited
|
Dec. 31, 2009
Qualia Clinical Services, Inc, and Veeda Laboratories Limited
Customer relationships acquired
Year
|
Dec. 31, 2011
Beacon Biosciences Inc
|
Dec. 31, 2008
Beacon Biosciences Inc
|
Jul. 01, 2004
Beacon Biosciences Inc
|
Dec. 31, 2008
Beacon Biosciences Inc
Customer relationships acquired
Year
|
Dec. 31, 2008
Beacon Biosciences Inc
Order Backlog
Year
|
Dec. 31, 2011
Prevalere Life Sciences
|
Nov. 14, 2008
Prevalere Life Sciences
Volunteer list acquired
Year
|
Dec. 31, 2011
Healthcare Discoveries Inc
|
Feb. 11, 2008
Healthcare Discoveries Inc
|
Feb. 11, 2008
Healthcare Discoveries Inc
Customer relationships acquired
Year
|
Feb. 11, 2008
Healthcare Discoveries Inc
Volunteer list acquired
Year
|
|
| Finite-Lived Intangible Assets [Line Items] | |||||||||||||||||||||||||
| Percentage of common stock acquired | 100.00% | 80.00% | 30.00% | 70.00% | 100.00% | ||||||||||||||||||||
| Value of amortizable intangible asset acquired | $ 5,200,000 | $ 1,200,000 | $ 11,200,000 | $ 1,400,000 | $ 6,600,000 | $ 600,000 | $ 800,000 | $ 400,000 | $ 200,000 | $ 1,500,000 | $ 7,400,000 | $ 1,600,000 | $ 1,300,000 | ||||||||||||
| Amortization period, minimum | 7 | 2 | |||||||||||||||||||||||
| Amortization period | 7.5 | 1.2 | 7.5 | 4.5 | 6.5 | 2 | 3 | 3 | 3 | 3 | 6 | ||||||||||||||
| Amortization period, maximum | 11 | 9 | |||||||||||||||||||||||
| Amount amortized in the period since the date of acquisition | $ 1,486,000 | $ 1,087,000 | $ 417,000 | $ 330,000 | $ 1,710,000 | $ 2,532,000 | $ 1,896,000 | ||||||||||||||||||
| X | ||||||||||
|
- Definition
The aggregate amount assigned to a major class of finite-lived intangible assets acquired either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Percentage of voting equity interests acquired in the business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate amount of intangible asset amortization recognized as expense during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average useful life of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The maximum useful life of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The minimum useful life of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Future intangible asset amortization expense (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended |
|---|---|
|
Dec. 31, 2011
|
|
| Finite-Lived Intangible Assets [Line Items] | |
| 2012 | $ 5,970 |
| 2013 | 4,534 |
| 2014 | 4,257 |
| 2015 | 4,208 |
| 2016 | 3,724 |
| Finite-Lived Intangible Assets, Future Amortization Expense, Total | $ 22,693 |
| X | ||||||||||
|
- Definition
The aggregate estimated amortization expense for succeeding fiscal years for intangible assets subject to amortization. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of amortization expense expected to be recognized during year five of the five succeeding fiscal years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of amortization expense expected to be recognized during year four of the five succeeding fiscal years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of amortization expense expected to be recognized during year one of the five succeeding fiscal years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of amortization expense expected to be recognized during year three of the five succeeding fiscal years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of amortization expense expected to be recognized during year two of the five succeeding fiscal years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Property Plant and Equipment Net (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Cost | ||
| Land | $ 4,602 | $ 3,597 |
| Building | 93,011 | 95,895 |
| Computer equipment and software | 178,477 | 155,547 |
| Office furniture and fixtures | 62,454 | 60,000 |
| Laboratory equipment | 32,134 | 31,260 |
| Leasehold improvements | 9,430 | 7,648 |
| Motor vehicles | 70 | 72 |
| Property, Plant and Equipment, Gross, Total | 380,178 | 354,019 |
| Less accumulated depreciation and asset write off | (211,717) | (183,158) |
| Property, plant and equipment (net) | $ 168,461 | $ 170,861 |
| X | ||||||||||
|
- Definition
Buildings, Gross No definition available.
|
| X | ||||||||||
|
- Definition
Computer Hardware And Software Transportation Equipment And Other Gross No definition available.
|
| X | ||||||||||
|
- Definition
Vehicles, Gross No definition available.
|
| X | ||||||||||
|
- Definition
The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Gross amount, at the balance sheet date, of long-lived, depreciable assets commonly used in offices and stores. Examples include desks, chairs, and store fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date of real estate held for productive use. This excludes land held for sale. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Gross amount, at the balance sheet date, of long-lived, depreciable assets that are an addition or improvement to assets held under lease arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Gross amount, as of the balance sheet date, of long-lived, depreciable assets used in the production process to produce goods and services. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Gross amount, at the balance sheet date, of long-lived physical assets used in the normal conduct of business and not intended for resale. This can include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Property Plant and Equipment Net - Additional Information (Detail) (USD $)
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Capital Leased Assets [Line Items] | ||
| Total cost of Assets held under capital finance leases | $ 825,000 | |
| Related accumulated depreciation | $ 518,000 |
| X | ||||||||||
|
- Definition
Property, plant, or equipment held under lease agreements classified as an asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The total charge for the use of long-lived depreciable assets subject to a lease meeting the criteria for capitalization. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Other Liabilities (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Other Liabilities [Line Items] | ||
| Personnel related liabilities | $ 62,017 | $ 54,983 |
| Facility related liabilities | 14,776 | 11,666 |
| General overhead liabilities | 24,520 | 24,052 |
| Other liabilities | 1,823 | 5,202 |
| Short term government grants | 79 | 111 |
| Restructuring provisions (note 14) | 3,874 | 315 |
| Acquisition consideration payable | 37,615 | 2,712 |
| Share repurchase program | 1,259 | |
| Short term finance leases (note 16) | 158 | |
| Other Liabilities | $ 145,963 | $ 99,199 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Short Term Lease Liabilities And Other, Current No definition available.
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for utilities, such as electrical power, heating oil, natural gas, and water. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Current portion of the fair value as of the acquisition date of potential payments under the contingent consideration arrangement, including cash and shares as applicable. No definition available.
|
| X | ||||||||||
|
- Definition
Total carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue or other forms of income in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Other Non-Current Liabilities (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Schedule of Accrued Liabilities [Line Items] | ||
| Defined benefit pension obligations, net (note 9) | $ 4,903 | $ 983 |
| Acquisition consideration payable | 11,903 | |
| Other non-current liabilities | 3,232 | 3,676 |
| Non-current other liabilities (Note 8) | $ 20,038 | $ 4,659 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Noncurrent portion of the fair value as of the acquisition date of potential payments under the contingent consideration arrangement, including cash and shares as applicable. No definition available.
|
| X | ||||||||||
|
- Definition
This represents the noncurrent liability recognized in the balance sheet that is associated with the defined benefit pension plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The noncurrent portion (due beyond one year or one operating cycle) of other accrued expenses (expenses incurred at the end of the reporting period but not yet paid) not otherwise defined in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Employee Benefits - Additional Information (Detail) (USD $)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Contributions | $ 134,000 | $ 133,000 | |
| Net gain for the defined benefit pension plan | |||
| Prior service cost for the defined benefit pension plan | |||
| Discount Rate Description | The discount rate is determined by reference to UK long dated government and corporate bond yields at the balance sheet date. This is represented by the iboxx AA 15 year plus return. | ||
| Expected overall rate of return on scheme assets | Expected long term rates of return to the asset distribution at December 31, 2011, gives rise to an expected overall rate of return of scheme assets of approximately 5.8% per annum. | ||
| Contribution to Pension fund | 300,000 | ||
| Expected benefit cashflow description | The expected cash flows are estimated figures based on the members expected to retire over the next 10 years assuming no early retirements plus an additional amount in respect of recent average withdrawal experience. | ||
| Retirement period used as a basis to estimate expected cash flows | 10 years | ||
| Expected long-term rate of return on assets | 5.80% | ||
| Long term equity risk-premium | 6.10% | ||
|
Legal and General over 15 year Gilts Index
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Risk free interest rate | 2.80% | ||
| Long term equity risk-premium | 3.10% | ||
| Expected long-term rate of return on bonds Description | The long-term expected return on bonds is determined by reference to UK long dated government and corporate bond yields at the balance sheet date. This is represented by the iboxx AA 15 year plus return. | ||
|
Defined Benefit Plan Contributions
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Contributions percentage of compensation | 6.00% | ||
| Contributions | 16,644,000 | 14,206,000 | 14,241,000 |
|
Defined Contribution Pension Plan 401k
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Participant's contributions percentage | 50.00% | ||
| Contributions percentage of compensation | 6.00% | ||
| Contributions | $ 7,064,000 | $ 6,603,000 | $ 5,189,000 |
| X | ||||||||||
|
- Definition
Defined Benefit Plan, Actual Return on Plan Assets Percentage No definition available.
|
| X | ||||||||||
|
- Definition
Defined Benefit Plan, Basis Used to Determine Overall Expected Long Term Rate of Returns on Assets Assumption No definition available.
|
| X | ||||||||||
|
- Definition
The company matches 50% of employee contributions which are up to 6% of their annual compensation. No definition available.
|
| X | ||||||||||
|
- Definition
Defined Benefit Plan, Prior Service Cost to be Amortized and Reclassified from Accumulated Other Comprehensive Income (Loss) to Net Pension Cost No definition available.
|
| X | ||||||||||
|
- Definition
Expected Retirement period No definition available.
|
| X | ||||||||||
|
- Definition
Maximum 401(k) Plan Contribution Rates as a Percentage of Employees Earnings No definition available.
|
| X | ||||||||||
|
- Definition
Rate of Return on Equity Securities No definition available.
|
| X | ||||||||||
|
- Definition
The amounts in accumulated other comprehensive income related to gains and losses that are not recognized immediately and are expected to be recognized as components of net periodic benefit cost over the next fiscal year that follows the most recent annual statement of financial position presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Description and explanation of the assumptions (including assumed discount rates, rates of compensation increase, and expected long-term rates of return on plan assets) used to calculate the benefit obligation and the assumptions used to calculate net periodic benefit cost. May also include other assumptions such as market-related value, average remaining service period, and average remaining life expectancy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of contributions made by plan participants. This item represents a periodic increase to the plan obligation and an increase to plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
A narrative description of the basis used to determine the overall expected long-term rate-of-return on assets assumption, such as the general approach used, the extent to which the overall rate-of-return on assets assumption was based on historical returns, the extent to which adjustments were made to those historical returns to reflect expectations of future returns, and how those adjustments were determined. The description would generally consider the major categories of assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
A description of a change in the reinvestment rate of return used as an underlying assumption for the prepayment estimates incorporated into cash flow projections for Collateralized Mortgage Obligations (CMOs) and Real Estate Mortgage Investment Conduits (REMICs). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Description of and general information regarding the types of plans utilized by the employer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash or cash equivalents contributed by the entity to fund its pension plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Change In Benefit Obligation (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Benefit obligation at beginning of year | $ 16,482 | $ 13,686 | |
| Service cost | 212 | 184 | 182 |
| Interest cost | 931 | 746 | 673 |
| Plan participants' contributions | 134 | 133 | |
| Benefits paid | (109) | (54) | |
| Actuarial loss | 2,621 | 2,232 | |
| Foreign currency exchange rate changes | (347) | (445) | |
| Benefit obligation at end of year | $ 19,924 | $ 16,482 | $ 13,686 |
| X | ||||||||||
|
- Definition
The net increase or decrease of changes in the value of either the benefit obligation or the plan assets resulting from experience different from that assumed or from a change in an actuarial assumption, or the consequence of a decision to temporarily deviate from the substantive plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
1) For defined benefit pension plans, the benefit obligation is the projected benefit obligation, which is the actuarial present value as of a date of all benefits attributed by the pension benefit formula to employee service rendered prior to that date. 2) For other postretirement defined benefit plans, the benefit obligation is the accumulated postretirement benefit obligation, which is the actuarial present value of benefits attributed to employee service rendered to a particular date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of payments made for which participants are entitled under a pension plan, including pension benefits, death benefits, and benefits due on termination of employment. Also includes payments made under a postretirement benefit plan, including prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services. This item represents a periodic decrease to the plan obligations and a decrease to plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of contributions made by plan participants. This item represents a periodic increase to the plan obligation and an increase to plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of increase or decrease in the benefit obligation attributed to foreign currency changes. The effects of foreign currency exchange rate changes that are to be disclosed are those applicable to plans of a foreign operation whose functional currency is not the reporting currency. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The actuarial present value of benefits attributed by the pension benefit formula to services rendered by employees during the period. The portion of the expected postretirement benefit obligation attributed to employee service during the period. The service cost component is a portion of the benefit obligation and is unaffected by the funded status of the plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Change In Plan Assets (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Defined Benefit Plan Disclosure [Line Items] | ||
| Fair value of plan assets at beginning of year | $ 15,499 | $ 13,573 |
| Actual return on plan assets | (604) | 2,003 |
| Employer contributions | 273 | 293 |
| Plan participants' contributions | 135 | 133 |
| Benefits paid | (109) | (54) |
| Foreign currency exchange rate changes | (173) | (449) |
| Fair value of plan assets at end of year | $ 15,021 | $ 15,499 |
| X | ||||||||||
|
- Definition
Defined Benefit Plan, Fair Value of Plan Assets, Benefits Paid No definition available.
|
| X | ||||||||||
|
- Definition
Defined Benefit Plan, Fair Value of Plan Assets, Contributions by Plan Participants No definition available.
|
| X | ||||||||||
|
- Definition
The difference between fair value of plan assets at the end of the period and the fair value at the beginning of the period, adjusted for contributions and payments of benefits during the period, and after adjusting for taxes and other expenses, as applicable. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase in the fair value of plan assets from contributions made by the employer. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Assets, usually stocks, bonds, and other investments, that have been segregated and restricted (usually in a trust) to provide benefits, at their fair value as of the measurement date. Plan assets include amounts contributed by the employer (and by employees for a contributory plan) and amounts earned from investing the contributions, less benefits paid. If a plan has liabilities other than for benefits, those non-benefit obligations may be considered as reductions of plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of increase or decrease in plan assets attributed to foreign currency changes. The effects of foreign currency exchange rate changes that are to be disclosed are those applicable to plans of a foreign operation whose functional currency is not the reporting currency. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Funded Status (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|---|---|---|---|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Projected benefit obligation | $ (19,924) | $ (16,482) | |
| Fair value of plan assets | 15,021 | 15,499 | 13,573 |
| Funded status | (4,903) | (983) | |
| Non-current other liabilities | $ (4,903) | $ (983) |
| X | ||||||||||
|
- Definition
The aggregate net amount recognized in the balance sheet associated with the defined benefit plan(s). Will normally be the same as the Defined Benefit Plan, Funded Status of Plan, Total. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Assets, usually stocks, bonds, and other investments, that have been segregated and restricted (usually in a trust) to provide benefits, at their fair value as of the measurement date. Plan assets include amounts contributed by the employer (and by employees for a contributory plan) and amounts earned from investing the contributions, less benefits paid. If a plan has liabilities other than for benefits, those non-benefit obligations may be considered as reductions of plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The funded status is measured as the difference between the fair value of plan assets and the benefit obligation. Will normally be the same as the net Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
If aggregate disclosures are presented, the aggregate projected benefit obligation for pension plans with accumulated benefit obligations in excess of plan assets as of the measurement date of each statement of financial position presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Components Of Net Periodic Benefit Cost (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Service cost | $ 212 | $ 184 | $ 182 |
| Interest cost | 931 | 746 | 673 |
| Expected return on plan assets | (1,141) | (980) | (740) |
| Amortization of prior service costs | 102 | ||
| Amortization of net (gain)/loss | (23) | ||
| Net periodic benefit (credit)/cost | $ 2 | $ (50) | $ 194 |
| X | ||||||||||
|
- Definition
The amount of gains or losses recognized in net periodic benefit cost. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of the prior service cost or credit recognized in net periodic benefit cost relating to benefit changes attributable to plan participants' prior service pursuant to a plan amendment or a plan initiation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
An amount calculated as a basis for determining the extent of delayed recognition of the effects of changes in the fair value of assets. The expected return on plan assets is determined based on the expected long-term rate of return on plan assets and the market-related value of plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total amount of net periodic benefit cost for defined benefit plans for the period. Periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The actuarial present value of benefits attributed by the pension benefit formula to services rendered by employees during the period. The portion of the expected postretirement benefit obligation attributed to employee service during the period. The service cost component is a portion of the benefit obligation and is unaffected by the funded status of the plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Net Periodic Pension Benefit Cost Assumptions (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Actuarial loss | $ 4,365 | $ 1,209 | $ 619 |
| Prior service costs recognized in other comprehensive income | 102 | ||
| Less actuarial loss recognized in net periodic benefit cost | 23 | ||
| Prior service costs recognized in net periodic benefit cost | (102) | ||
| Total | $ 4,365 | $ 1,209 | $ 642 |
|
Pension Plans, Defined Benefit
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Discount rate | 5.40% | 5.70% | 6.40% |
| Rate of compensation increase | 4.00% | 4.00% | 4.20% |
| Expected rate of return on plan assets | 7.10% | 7.40% | 6.80% |
| X | ||||||||||
|
- Definition
Defined Benefit Plan, Actuarial Losses to be Amortized and Reclassified from Accumulated Other Comprehensive Income (Loss) to Net Pension Cost No definition available.
|
| X | ||||||||||
|
- Definition
Other Comprehensive Income, Amortization of Net Actuarial Gain (Loss), Net of Tax No definition available.
|
| X | ||||||||||
|
- Definition
The interest rate used to adjust for the time value of money. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
An assumption as to the rate of return on plan assets reflecting the average rate of earnings expected on the funds invested or to be invested to provide for the benefits included in the benefit obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Expected rate of compensation increases (for pay-related plans). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The adjustment out of other comprehensive income for prior service costs recognized as a component of net period benefit cost during the period, after tax. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cost (credit) resulting from a plan amendment that occurred during the period, after tax. The cost has not been recognized in net periodic benefit cost. A plan amendment includes provisions that grant increased benefits based on service rendered in prior periods. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The adjustment out of other comprehensive income for the net transition asset or obligation recognized as a component of net periodic benefit cost during the period, after tax. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Amounts Recognized In Accumulated Other Comprehensive Income That Has Not Yet Been Recognized As Components Of Net Periodic Benefit Cost (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|---|---|---|---|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Net actuarial (gain)/loss | $ 4,060 | $ (305) | $ (1,514) |
| Total | $ 4,060 | $ (305) | $ (1,514) |
| X | ||||||||||
|
- Definition
Defined Benefit Plan, Accumulated Other Comprehensive Income, Net Of Tax No definition available.
|
| X | ||||||||||
|
- Definition
The total of net gain (loss), prior service cost (credit), and transition assets (obligations), as well as minimum pension liability if still remaining, included in accumulated other comprehensive income associated with a defined benefit pension or other postretirement plan(s) because they have yet to be recognized as components of net periodic benefit cost. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Assumptions Used In Determining The Benefit Obligation (Detail)
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Defined Benefit Plan Disclosure [Line Items] | ||
| Discount rate | 4.70% | 5.40% |
| Rate of compensation increase | 3.50% | 4.00% |
| X | ||||||||||
|
- Definition
The interest rate used to adjust for the time value of money for the plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Expected rate of compensation increases (for pay-related plans). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Expected Long Term Rates of Return on Different Asset Classes (Detail)
|
12 Months Ended |
|---|---|
|
Dec. 31, 2011
|
|
| Defined Benefit Plan Disclosure [Line Items] | |
| Equity - Expected long-term return per annum | 6.10% |
| Bonds - Expected long-term return per annum | 4.70% |
| X | ||||||||||
|
- Definition
Rate Of Return On Debt Securities No definition available.
|
| X | ||||||||||
|
- Definition
Rate of Return on Equity Securities No definition available.
|
| X | ||||||||||
|
- Details
|
|
Underlying Asset Split of Fund (Detail)
|
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Defined Benefit Plan Disclosure [Line Items] | ||
| Equity - Underlying asset split | 90.00% | 90.00% |
| Bonds - Underlying asset split | 10.00% | 10.00% |
| Total underlying asset split | 100.00% | 100.00% |
| X | ||||||||||
|
- Definition
Defined Benefit Plan, Assets Target Allocations, Total No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Target allocation percentage of investments in debt securities to total plan assets presented on a weighted-average basis as of the measurement date of the latest statement of financial position. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Target allocation percentage of investments in equity securities to total plan assets presented on a weighted-average basis as of the measurement date of the latest statement of financial position. No definition available.
|
|
Plan Asset Fair Value Measurements (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|---|---|---|---|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | $ 15,021 | $ 15,499 | $ 13,573 |
|
Fair Value, Inputs, Level 1
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | 15,021 | ||
|
Fair Value, Inputs, Level 1 | Cash
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | 2 | ||
|
Fair Value, Inputs, Level 1 | Equity Securities | Legal and General UK Equity Index
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | 5,426 | ||
|
Fair Value, Inputs, Level 1 | Equity Securities | Legal and General North America Equity Index
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | 2,772 | ||
|
Fair Value, Inputs, Level 1 | Equity Securities | Legal and General Europe (ex UK) Equity Index
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | 2,696 | ||
|
Fair Value, Inputs, Level 1 | Equity Securities | Legal and General Japan Equity Index
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | 1,329 | ||
|
Fair Value, Inputs, Level 1 | Equity Securities | Legal and General Asia Pac (ex Japan) Equity Index
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | 1,301 | ||
|
Fair Value, Inputs, Level 1 | Fixed Income Securities | Legal and General over 15 year Gilts Index
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | 495 | ||
|
Fair Value, Inputs, Level 1 | Fixed Income Securities | Legal and General AAA-AA-A Bonds Over 15 year Index
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | 499 | ||
|
Fair Value, Inputs, Level 1 | Fixed Income Securities | Legal and General over 5 year Index-Linked Gilts Index
|
|||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Fair value of plan assets | $ 501 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Assets, usually stocks, bonds, and other investments, that have been segregated and restricted (usually in a trust) to provide benefits, at their fair value as of the measurement date. Plan assets include amounts contributed by the employer (and by employees for a contributory plan) and amounts earned from investing the contributions, less benefits paid. If a plan has liabilities other than for benefits, those non-benefit obligations may be considered as reductions of plan assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Annual Benefit Payments (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
|---|---|
| Defined Benefit Plan Disclosure [Line Items] | |
| Expected future benefit payments in 2012 | $ 78 |
| Expected future benefit payments in 2013 | 78 |
| Expected future benefit payments in 2014 | 78 |
| Expected future benefit payments in 2015 | 78 |
| Expected future benefit payments in 2016 | 78 |
| Expected future benefit payments in years 2017 - 2021 | $ 385 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of the aggregate benefits expected to be paid in the five fiscal years thereafter (the aggregate amount of benefits expected to be paid in years 6 through 10 after the date of the latest statement of financial position). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of the benefits expected to be paid in Year 5. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of the benefits expected to be paid in Year 4. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of the benefits expected to be paid in Year 1. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of the benefits expected to be paid in Year 3. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of the benefits expected to be paid in Year 2. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Share Options and Stock Compensation Charges - Additional Information (Detail) (USD $)
|
12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
Year
|
Dec. 31, 2010
|
Dec. 31, 2009
|
Dec. 31, 2011
Employee Stock Plan, 2008 Plan
|
Dec. 31, 2011
Employee Stock Plan, 2008 Plan
Minimum
|
Dec. 31, 2011
Employee Stock Plan, 2008 Plan
Individual Employee
|
Jul. 21, 2008
Restricted Stock Units 2008
|
Dec. 31, 2011
Employee Stock Plan, 2003 Plan
|
Dec. 31, 2011
Employee Stock Plan, 2003 Plan
Individual Employee
|
Dec. 31, 2011
Stock Option
|
Dec. 31, 2011
Stock Option
Maximum
Year
|
Dec. 31, 2011
Stock Option And Award Plans
|
Dec. 31, 2011
Stock Option And Award Plans
Fully Vested Options
|
May 20, 2011
Restricted Stock Units (RSUs)
|
Aug. 16, 2010
Restricted Stock Units (RSUs)
|
Aug. 07, 2008
Restricted Stock Units (RSUs)
|
Dec. 31, 2011
Restricted Stock Units (RSUs)
|
Aug. 07, 2008
Restricted Stock Units (RSUs)
Minimum
|
Aug. 07, 2008
Restricted Stock Units (RSUs)
Maximum
|
|
| Compensation Related Costs Share Based Payments Disclosure [Line Items] | |||||||||||||||||||
| Percentage of option price for fair value of ordinary share | 100.00% | ||||||||||||||||||
| Ordinary shares which have been reserved for issuance | 6,000,000 | 400,000 | 1,000,000 | 6,000,000 | 400,000 | ||||||||||||||
| Maximum number of award as percentage of shares outstanding | 10.00% | ||||||||||||||||||
| Shares vesting period | 5 years | ||||||||||||||||||
| Shares expiration period | 8 years | ||||||||||||||||||
| Weighted Average Remaining Contractual Life of Options Outstanding | 4.68 | 8 | |||||||||||||||||
| Weighted Average Remaining Contractual Life of Options Exercisable | 3.26 | ||||||||||||||||||
| Options Expected to Vest | 854,424 | ||||||||||||||||||
| Intrinsic Value Of Options Exercised | $ 2,900,000 | ||||||||||||||||||
| Intrinsic Value Of Options Outstanding | 6,000,000 | ||||||||||||||||||
| Intrinsic Value Of Options Exercisable | 5,900,000 | ||||||||||||||||||
| Fair value of stock awards vested | 100,000 | 100,000 | |||||||||||||||||
| Non-cash stock compensation expense | 9,355,000 | 7,408,000 | 7,353,000 | ||||||||||||||||
| Non-cash stock compensation expense not yet recognized | 20,600,000 | ||||||||||||||||||
| Unrecognized stock-based compensation expense, weighted average period (years) | 3.0 | ||||||||||||||||||
| Tax benefit on exercise of options | $ 681,000 | $ 2,345,000 | $ 487,000 | ||||||||||||||||
| Options granted, exercise price range minimum | $ 8.60 | $ 8.60 | |||||||||||||||||
| Options granted, at exercise prices maximum | $ 41.25 | $ 18.00 | |||||||||||||||||
| Options vesting period | 5 years | ||||||||||||||||||
| Awards granted to certain key employees | 6,280 | 365,000 | |||||||||||||||||
| Market price of the Company's ordinary shares on date of award | $ 41.95 | ||||||||||||||||||
| Ordinary shares issued by the Company | 3,768 | 2,512 | |||||||||||||||||
| Vesting dates, earliest | Feb. 26, 2009 | Feb. 26, 2011 | |||||||||||||||||
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Maximum Percentage Of Outstanding Share Based Payment Award As Percentage Of Shares Outstanding No definition available.
|
| X | ||||||||||
|
- Definition
Percentage of Fair Market Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Market Price of the Shares at Date of Grant No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other Than Options, Vesting Date No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement By Share Based Payment Award Expiry Period From Date Of Grant No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award Vesting Period No definition available.
|
| X | ||||||||||
|
- Definition
Tax benefit associated with any equity-based compensation plan other than an employee stock ownership plan (ESOP). The tax benefit results from the deduction by the entity on its tax return for an award of stock that exceeds the cumulative compensation cost for common stock or preferred stock recognized for financial reporting. Includes any resulting tax benefit that exceeds the previously recognized deferred tax asset (excess tax benefits). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
As of the balance sheet date, the aggregate unrecognized cost of equity-based awards made to employees under equity-based compensation awards that have yet to vest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, using a decimal to express in number of years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Description of the period of time over which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, which may be expressed in a variety of ways (for example, in years, month and year). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total fair value of equity-based awards for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total dollar difference between fair values of the underlying shares reserved for issuance and exercise prices of vested portions of options outstanding and currently exercisable under the option plan as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total accumulated difference between fair values of underlying shares on dates of exercise and exercise price on options which were exercised (or share units converted) into shares during the reporting period under the plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The total dollar difference between fair values of the underlying shares reserved for issuance and exercise prices pertaining to options outstanding under the plan as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average period between the balance sheet date and expiration for all awards outstanding under the plan, which may be expressed in a decimal value for number of years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted-average period between the balance sheet date and expiration date for fully vested and expected to vest options that are exercisable (or convertible) under the plan, which may be expressed in a decimal value for number of years. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Summary of Stock Option Activity (Detail) (Stock Option And Award Plans, USD $)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
|
Stock Option And Award Plans
|
|||
| Options Granted Under Plans | |||
| Beginning balance | 4,798,677 | 5,408,222 | 5,222,263 |
| Granted | 989,449 | 1,038,327 | 932,133 |
| Exercised | (430,340) | (1,237,015) | (489,370) |
| Cancelled | (454,968) | (410,857) | (256,804) |
| Ending Balance | 4,902,818 | 4,798,677 | 5,408,222 |
| Vested and exercisable at end of period | 2,368,508 | ||
| Number of Shares | |||
| Beginning balance | 4,798,677 | 5,408,222 | 5,222,263 |
| Granted | 989,449 | 1,038,327 | 932,133 |
| Exercised | (430,340) | (1,237,015) | (489,370) |
| Cancelled | (454,968) | (410,857) | (256,804) |
| Ending balance | 4,902,818 | 4,798,677 | 5,408,222 |
| Vested and exercisable at end of period | 2,368,508 | ||
| Weighted Average Exercise Price | |||
| Beginning balance | $ 21.71 | $ 18.99 | $ 17.98 |
| Granted | $ 19.66 | $ 24.34 | $ 21.54 |
| Exercised | $ 10.84 | $ 10.64 | $ 9.03 |
| Cancelled | $ 25.77 | $ 25.86 | $ 26.60 |
| Ending balance | $ 21.87 | $ 21.71 | $ 18.99 |
| Vested and exercisable at end of period | $ 20.35 | ||
| Weighted Average Grant Date Fair Value | |||
| Beginning balance | $ 8.47 | $ 7.60 | $ 7.24 |
| Granted | $ 8.20 | $ 9.08 | $ 8.47 |
| Exercised | $ 4.80 | $ 4.69 | $ 4.07 |
| Cancelled | $ 9.87 | $ 9.91 | $ 10.09 |
| Ending balance | $ 8.61 | $ 8.47 | $ 7.60 |
| Vested and exercisable at end of period | $ 8.08 | ||
| X | ||||||||||
|
- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for Additional Grant No definition available.
|
| X | ||||||||||
|
- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Outstanding, Number No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Grants in Period No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant, Options Cancelled In Period No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant, Options Exercised In Period No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Options, Exercisable and Vested, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Options, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The weighted average price at which option holders acquired shares when converting their stock options into shares under the plan during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that lapsed during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net number of share options (or share units) granted during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on stock options awarded under the plan during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The weighted average price as of the beginning of the year at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Schedule of Movement in Non-Vested Share Options (Detail) (Stock Option, USD $)
|
12 Months Ended |
|---|---|
|
Dec. 31, 2011
|
|
|
Stock Option
|
|
| Number of Shares | |
| Beginning Balance | 2,673,674 |
| Granted | 989,449 |
| Vested | (836,737) |
| Forfeited | (292,076) |
| Ending Balance | 2,534,310 |
| Weighted Average Exercise Price | |
| Beginning Balance | $ 24.76 |
| Granted | $ 19.66 |
| Vested | $ 23.00 |
| Forfeited | $ 26.31 |
| Ending Balance | $ 23.30 |
| Weighted Average Fair Value | |
| Beginning Balance | $ 9.48 |
| Granted | $ 8.20 |
| Vested | $ 9.01 |
| Forfeited | $ 10.00 |
| Ending Balance | $ 9.11 |
| X | ||||||||||
|
- Definition
ShareBased Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeited In Period No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Forfeited in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Forfeited in Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Granted in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Granted in Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
ShareBased Compensation Arrangement By Share Based Payment Award Nonvested Options Grants In Period No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Outstanding, Number No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Outstanding Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
ShareBased Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Vested in Period Weighted Average Exercise Price No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Vested in Period Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Nonvested Options, Weighted Average Grant Date Fair Value No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted-average period remaining as of the balance sheet date until option expiration pertaining to the outstanding stock options for all option plans in the customized range of exercise prices, which may be expressed in a variety of ways (for example, years, months). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Schedule of Weighted Average Fair Values and Assumptions Used (Detail) (Stock Option, USD $)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
Year
|
Dec. 31, 2010
Year
|
Dec. 31, 2009
Year
|
|
|
Stock Option
|
|||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
| Weighted average fair value | $ 8.20 | $ 9.08 | $ 8.47 |
| Assumptions: | |||
| Expected volatility | 45.00% | 45.00% | 45.00% |
| Dividend yield | 0.00% | 0.00% | 0.00% |
| Risk-free interest rate | 1.40% | 1.50% | 0.20% |
| Expected life | 5.00 | 4.05 | 5.11 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The period of time an equity-based award is expected to be outstanding. An equity-based award's expected term is generally determined based on, among other factors, the instrument's contractual term and the effects of employees' expected exercise and post-vesting employment termination behavior. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Market Price of the Shares at Date of Grant No definition available.
|
| X | ||||||||||
|
- Definition
Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other Than Options, Vesting Date No definition available.
|
| X | ||||||||||
|
- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Grant Date No definition available.
|
| X | ||||||||||
|
- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Restricted Share Units (RSUs) Awarded to Certain Key Executives (Parenthetical) (Detail) (Restricted Stock Units (RSUs))
|
1 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
|
Aug. 07, 2008
|
Dec. 31, 2011
|
||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
| RSU's Awarded | 6,280 | 365,000 | |||
|
Group 2
|
|||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
| RSU's Awarded | 120,000 | [1] | |||
|
Retired CEO Mr. Peter Gray | Group 2
|
|||||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
| RSU's Awarded | 100,000 | ||||
|
|||||
| X | ||||||||||
|
- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Movement in Non-vested Restricted Share Units (Detail) (Restricted Stock Units (RSUs), USD $)
|
1 Months Ended | 12 Months Ended |
|---|---|---|
|
Aug. 07, 2008
|
Dec. 31, 2011
|
|
|
Restricted Stock Units (RSUs)
|
||
| Number of Units | ||
| Beginning Balance | 1,256 | |
| Granted | 6,280 | 365,000 |
| Vested | (1,256) | |
| Ending Balance | 365,000 | |
| Weighted Average Fair Value | ||
| Beginning Balance | $ 41.95 | |
| Granted | $ 19.46 | |
| Vested | $ 41.95 | |
| Ending Balance | $ 19.46 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Non-Cash Stock Compensation Expense (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
| Share-based compensation expense | $ 9,355 | $ 7,408 | $ 7,353 |
|
Cost of Sales
|
|||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
| Share-based compensation expense | 5,155 | 4,049 | 3,776 |
|
Selling, General and Administrative Expense
|
|||
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
| Share-based compensation expense | $ 4,200 | $ 3,359 | $ 3,577 |
| X | ||||||||||
|
- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Government Grants (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
| Received | $ 3,133 | $ 3,126 |
| Less accumulated amortization | (1,994) | (1,879) |
| Foreign exchange translation adjustment | 291 | 334 |
| Deferred Revenue and Credits, Total | 1,430 | 1,581 |
| Less current portion | (79) | (111) |
| Non-current government grants | $ 1,351 | $ 1,470 |
| X | ||||||||||
|
- Definition
Accumulated Amortization, Capital Government Grants No definition available.
|
| X | ||||||||||
|
- Definition
Capital Government Grants Current No definition available.
|
| X | ||||||||||
|
- Definition
Noncurrent capital government grants, which are amortized and recognized in earnings over the grant period. No definition available.
|
| X | ||||||||||
|
- Definition
Deferred Items Grants From Outside Parties No definition available.
|
| X | ||||||||||
|
- Definition
Foreign Currency Translation Adjustment No definition available.
|
| X | ||||||||||
|
- Definition
Total carrying amount of consideration received or receivable as of the balance sheet date representing potential earnings that were not as yet recognized as revenue or other forms of income in conformity with GAAP. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Government Grants - Additional Information (Detail) (USD $)
|
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Financing Receivable, Recorded Investment, Past Due [Line Items] | ||
| Government grants amortized to the profit and loss account | $ 115,000 | $ 220,000 |
| Restricted retained earnings | $ 1,400,000 | |
| X | ||||||||||
|
- Definition
The amortization of capital government grants which are amortized and recognized in earnings over the grant period. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Share Capital - Additional Information (Detail) (USD $)
|
12 Months Ended | 1 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
Oct. 27, 2011
Maximum
|
Nov. 22, 2011
Plan 1
|
Nov. 22, 2011
Plan 2
|
Dec. 31, 2011
Employee Stock Option
|
Dec. 31, 2010
Employee Stock Option
|
Dec. 31, 2009
Employee Stock Option
|
Dec. 31, 2011
Restricted Stock Units (RSUs)
|
Dec. 31, 2010
Restricted Stock Units (RSUs)
|
|
| Employee Stock Ownership Plan (ESOP) Disclosures [Line Items] | |||||||||
| Share allotment description | Every holder of an ordinary share present in person or proxy at a general meeting of shareholders shall have one vote, for each ordinary share held with no individual having more than one vote. | ||||||||
| Ordinary shares repurchased | 545,597 | ||||||||
| Ordinary shares repurchased, value | $ 9,005,000 | ||||||||
| Options exercised by employees | 430,340 | 1,237,015 | 489,370 | ||||||
| Average exercise price of Option per share | $ 10.84 | $ 10.64 | $ 9.03 | ||||||
| Total proceeds from exercise of stock options by employees | 4,700,000 | 13,200,000 | 4,400,000 | ||||||
| Ordinary shares issued in respect of certain RSU's previously awarded by the Company | 3,768 | 2,512 | |||||||
| Share repurchase program value | $ 50,000,000 | $ 10,000,000 | $ 10,000,000 | ||||||
| Share repurchase plans, start date | Nov. 23, 2011 | Jan. 01, 2012 | |||||||
| Share repurchase plans, end date | Dec. 31, 2011 | Feb. 20, 2012 | |||||||
| X | ||||||||||
|
- Definition
Share Repurchase Program, Repurchase Period End Date No definition available.
|
| X | ||||||||||
|
- Definition
Share Repurchase Program, Repurchase Period Start Date No definition available.
|
| X | ||||||||||
|
- Definition
Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The weighted average price at which option holders acquired shares when converting their stock options into shares under the plan during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares that have been repurchased and retired during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount authorized by an entity's Board of Directors under a stock repurchase plan. No definition available.
|
|
Components of Income Before Provision for Income Tax Expense (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Schedule of Components of Income Before Income Tax Expense (Benefit) [Line Items] | |||
| Income before provision for income taxes | $ 28,995 | $ 92,724 | $ 104,674 |
|
Ireland
|
|||
| Schedule of Components of Income Before Income Tax Expense (Benefit) [Line Items] | |||
| Income before provision for income taxes | (33,732) | 37,298 | 51,783 |
|
U.S.
|
|||
| Schedule of Components of Income Before Income Tax Expense (Benefit) [Line Items] | |||
| Income before provision for income taxes | 13,317 | 12,276 | 12,997 |
|
Other
|
|||
| Schedule of Components of Income Before Income Tax Expense (Benefit) [Line Items] | |||
| Income before provision for income taxes | $ 49,410 | $ 43,150 | $ 39,894 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Components of Total Income Tax Expense (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Current: | |||
| Current tax | $ 12,236 | $ 3,319 | $ 13,728 |
| Deferred expense/(benefit): | |||
| Deferred tax expense/(benefit) | (6,121) | 2,334 | (3,353) |
| Provision for income taxes | 6,115 | 5,653 | 10,375 |
| Impact on shareholders equity of the tax consequence of : | |||
| Stock compensation expense | (681) | (2,345) | (487) |
| Currency impact of long term funding | (294) | 198 | 1,142 |
| Total | 5,140 | 3,506 | 11,030 |
|
Ireland
|
|||
| Current: | |||
| Current tax | 351 | 4,522 | (3,841) |
| Deferred expense/(benefit): | |||
| Deferred tax expense/(benefit) | (3,825) | 788 | (703) |
| Provision for income taxes | (3,475) | 5,310 | (4,544) |
|
U.S.
|
|||
| Current: | |||
| Current tax | 6,367 | (1,915) | 9,492 |
| Deferred expense/(benefit): | |||
| Deferred tax expense/(benefit) | (1,711) | 1,322 | (1,672) |
| Provision for income taxes | 4,656 | (593) | 7,820 |
|
Rest of Europe and Other
|
|||
| Current: | |||
| Current tax | 5,518 | 712 | 8,077 |
| Deferred expense/(benefit): | |||
| Deferred tax expense/(benefit) | $ (585) | $ 224 | $ (978) |
| X | ||||||||||
|
- Definition
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Long Term Funding Tax No definition available.
|
| X | ||||||||||
|
- Definition
Total Deferred Income Tax Expense (Benefit) No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The component of income tax expense for the period representing amounts of income taxes paid or payable (or refundable) for the period for all income tax obligations as determined by applying the provisions of relevant enacted tax laws to relevant amounts of taxable Income or Loss from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Reductions in the entity's income taxes that arise when compensation cost (from non-qualified share-based compensation) recognized on the entity's tax return exceeds compensation cost from equity-based compensation recognized in financial statements. This element represents the cash inflow reported in the enterprise's financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Tax effect of the change in accumulated other comprehensive income (loss), that is, the tax effect on items included in other comprehensive income (loss) during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Income Taxes - Additional Information (Detail) (USD $)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Ireland's statutory income tax rate | 12.50% | 12.50% | 12.50% |
| Deferred tax asset | $ 24,741,000 | $ 16,740,000 | $ 17,551,000 |
| Deferred tax asset Non-Current | 10,076,000 | 10,028,000 | |
| Deferred tax liability | 21,581,000 | 15,907,000 | 14,475,000 |
| Deferred tax liability Non current | 20,395,000 | 13,862,000 | |
| Deferred tax liability unrecognized for the undistributed earnings of foreign subsidiaries | 0 | 0 | 0 |
| Total unrecognized tax benefits net of potential benefits | 6,500,000 | 8,100,000 | 15,400,000 |
| Valuation allowance for deferred tax assets | 16,445,000 | 12,290,000 | 10,411,000 |
| Net change in the total valuation allowance | 4,100,000 | 1,900,000 | |
| Interest and penalties recognized as an expense | 400,000 | 1,800,000 | |
| Total accrued interest and penalties | 1,200,000 | 1,700,000 | |
| Tax Jurisdiction Description | In the United States tax periods open to audit include the years ended December 31, 2008 December 31, 2009 December 31, 2010 and December 31, 2011. In Ireland tax periods open to audit include the years ended December 31, 2007, December 31, 2008, December 31, 2009, December 31, 2010 and December 31, 2011. During such audits, local tax authorities may challenge the positions taken by us in tax returns. | ||
|
Foreign Country
|
|||
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Non-U.S subsidiaries Operating loss carry forwards for income tax | 83,100,000 | 43,300,000 | |
| Additional operating loss carry forward | 5,600,000 | ||
| Expiration period | Expire between 2012 and 2014 | ||
|
Central Laboratory
|
|||
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Expiration period | Expire between 2012 and 2031 | ||
| U.S. Federal net operating loss carry forwards currently available for offset | 3,900,000 | ||
| State net operating loss carry forwards carry forwards currently available for offset | 12,100,000 | ||
| Operating Loss Carry forwards Limitation Per Year | 113,000 | ||
| Limitation description | Due to the subsidiary experiencing a change of ownership in 2000, as defined by Section 382 of the Internal Revenue Code of 1986, as amended. | ||
| Alternative minimum tax credit carry forwards | 300,000 | ||
| Business credit carry forwards that are available to offset | 300,000 | ||
|
Central Laboratory | Internal Revenue Service (IRS)
|
|||
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Additional operating loss carry forward | 4,900,000 | ||
| State net operating loss carry forwards remaining | 1,000,000 | ||
|
Central Laboratory | State
|
|||
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Additional operating loss carry forward | 13,084,000 | ||
| State net operating loss carry forwards remaining | 1,000,000 | ||
|
Clinical Research
|
|||
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Alternative minimum tax credit carry forwards | 100,000 | ||
| Tax credit carry forwards expiration period | Begin to expire in 2012 | ||
|
Clinical Research | State
|
|||
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Additional operating loss carry forward | 1,235,000 | ||
| Expiration period | Expire between 2020 and 2031 | ||
|
Oxford Outcomes Limited
|
|||
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Expiration period | Expire between 2030 and 2032 | ||
|
Oxford Outcomes Limited | Internal Revenue Service (IRS)
|
|||
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Additional operating loss carry forward | 800,000 | ||
|
Oxford Outcomes Limited | State
|
|||
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Additional operating loss carry forward | $ 900,000 | ||
|
Ireland
|
|||
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Ireland's statutory income tax rate | 12.50% | ||
| X | ||||||||||
|
- Definition
Operating Loss Carryforwards Limitation Per Year No definition available.
|
| X | ||||||||||
|
- Definition
Operating Loss Carryforwards, State and Local No definition available.
|
| X | ||||||||||
|
- Definition
Operating Loss Carryforwards Subject To Limitation No definition available.
|
| X | ||||||||||
|
- Definition
Operating Loss Carryforwards, US Federal No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Unrecognized Tax Benefits Increase Resulting From Prior Period Tax Positions Net of Tax No definition available.
|
| X | ||||||||||
|
- Definition
The aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; net of deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The noncurrent portion as of the balance sheet date of the aggregate carrying amount of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after the valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, is classified according to the expected reversal date of the temporary difference. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of operating loss carryforwards available to reduce future taxable income, which are not subject to expiration dates. No definition available.
|
| X | ||||||||||
|
- Definition
The amount of operating loss carryforwards available to reduce future taxable income, which are subject to expiration dates. No definition available.
|
| X | ||||||||||
|
- Definition
The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused alternative minimum tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceeded statutory limits on inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused general business tax credit carryforwards. The general business tax credits are the sum of numerous tax credits which include, but are not limited to, investment tax , alcohol fuels, low income housing, alternative fuels, alternative motor vehicles, hurricane relief, disabled access, renewable resources electricity production, employer social security, orphan drug, new markets, employer provided child care facilities and services, biodiesel fuels, low sulfur diesel fuel production, distilled spirits, and the advanced nuclear power facilities credit. A tax credit carryforward is the amount by which tax credits available for utilization exceeded statutory limits on inclusion in historical filings. They can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of the portions of deferred tax assets as of the balance sheet date for which, based on the weight of available evidence, it is more likely than not will not be realized through future reductions of tax-based income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cumulative amount of all deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A taxable temporary difference is a difference between the tax basis and the carrying amount of an asset or liability in the financial statements prepared in accordance with generally accepted accounting principles that will result in taxable amounts in one or more future periods. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise separates deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount as of the balance sheet date of the estimated future tax effects attributable to undistributed earnings of subsidiaries and other recognized entities in countries outside the country of domicile which will increase future taxable income when such earnings are distributed into the country of domicile. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The domestic federal statutory tax rate applicable under enacted tax laws to the Company's pretax income from continuing operations for the period. The "statutory" tax rate is the regular tax rate if there are alternative tax systems. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Identification, by major jurisdiction, of tax years that remain open to examination under enacted tax laws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income. No definition available.
|
| X | ||||||||||
|
- Definition
State the expiration dates of the tax credit carryforward. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the total of accruals as of the date of the statement of financial position for interest recognized for an underpayment of income taxes computed by applying the applicable statutory rate of interest to the difference between a tax position recognized for financial reporting purposes and the amount previously taken or expected to be taken in a tax return of the entity and the amount of statutory penalties for a tax position claimed or expected to be claimed by the entity, in its tax return, that does not meet the minimum statutory threshold to avoid payment of penalties. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This element represents the total of interest expense recognized for an underpayment of income taxes computed by applying the applicable statutory rate of interest to the difference between a tax position recognized for financial reporting purposes and the amount previously taken or expected to be taken in a tax return of the entity and the amount of statutory penalties in the period in which the entity claims or expects to claim a tax position, in its tax return, that does not meet the minimum statutory threshold to avoid payment of penalties. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of the change in the period in the valuation allowance for a specified deferred tax asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Consolidated Effective Tax Rate Differed from Statutory Rate (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Taxes at Irish statutory rate of 12.5% (2010:12.5%; 2011: 12.5%) | $ 3,625 | $ 11,590 | $ 13,084 |
| Foreign and other income taxed at higher/(reduced) rates | 5,373 | (4,765) | 9,319 |
| Research & development tax incentives | (6,341) | (1,927) | (15,872) |
| Movement in valuation allowance | 4,362 | 822 | 4,027 |
| Prior year over provision in respect of foreign taxes | (83) | (285) | (329) |
| Effects of permanent items | (615) | 97 | 65 |
| Other | (206) | 121 | 81 |
| Provision for income taxes | $ 6,115 | $ 5,653 | $ 10,375 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to changes in the valuation allowance for deferred tax assets in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference, between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to total foreign income tax expense or benefit. The foreign income tax expense or benefit difference represents the income tax expense or benefit at applicable domestic statutory income tax rates applied to foreign earnings or loss for the period versus the foreign income tax expense or benefit calculated by applying the appropriate foreign tax rates. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to nondeductible research and development expenses, including in-process research and development acquired as part of a business combination, under enacted tax laws. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference, between total income tax expense or benefit as reported in the Income Statement for the year/accounting period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to all other items not otherwise listed in the existing taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of other amounts reflected in the reconciliation of the statutory tax provision (benefit) to the actual tax provision (benefit). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the current period and the expected income tax expense or benefit computed attributable to revisions of previously reported income tax expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Consolidated Effective Tax Rate Differed from Statutory Rate (Parenthetical) (Detail)
|
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Schedule of Deferred Income Tax Assets and Liabilities [Line Items] | |||
| Irish statutory rate | 12.50% | 12.50% | 12.50% |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The domestic federal statutory tax rate applicable under enacted tax laws to the Company's pretax income from continuing operations for the period. The "statutory" tax rate is the regular tax rate if there are alternative tax systems. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Tax Assets and Deferred Tax Liabilities (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|---|---|---|---|
| Deferred tax liabilities: | |||
| Property, plant and equipment | $ 7,331 | $ 6,645 | $ 6,100 |
| Goodwill and related assets | 9,443 | 8,055 | 6,301 |
| Other intangible assets | 3,525 | 223 | 1,312 |
| Accruals | 1,185 | 149 | 12 |
| Other | 97 | 835 | 750 |
| Total deferred tax liabilities recognized | 21,581 | 15,907 | 14,475 |
| Deferred tax assets: | |||
| Net operating loss carry forwards | 21,981 | 16,580 | 12,826 |
| Property, plant and equipment | 1,324 | 882 | 1,090 |
| Accrued expenses and payments on account | 11,652 | 6,607 | 9,313 |
| Stock options | 4,818 | 3,522 | 3,547 |
| Deferred compensation expense | 1,197 | 1,349 | 947 |
| Other | 214 | 90 | 239 |
| Total deferred tax assets | 41,186 | 29,030 | 27,962 |
| Valuation allowance for deferred tax assets | (16,445) | (12,290) | (10,411) |
| Deferred tax assets recognized | 24,741 | 16,740 | 17,551 |
| Net deferred tax asset | $ 3,160 | $ 833 | $ 3,076 |
| X | ||||||||||
|
- Definition
Deferred Tax Assets, Property Plant And Equipment No definition available.
|
| X | ||||||||||
|
- Definition
Deferred Tax Liabilities Miscellaneous Accruals No definition available.
|
| X | ||||||||||
|
- Definition
The sum of the tax effects as of the balance sheet date of the amounts of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws ( before the valuation allowance, if any, to reduce such sum amount to net realizable value). Includes any tax benefit realized in deferred tax assets for significant impacts of tax planning strategies. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For entities that net deferred tax assets and tax liabilities, represents the unclassified net amount of deferred tax assets and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities. A temporary difference is a difference between the tax basis of an asset or liability and its carrying amount in the financial statements prepared in accordance with generally accepted accounting principles that will reverse in ensuing periods. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; net of deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The sum of the tax effects as of the balance sheet date of the amount of excesses of tax deductions over gross income in a year which cannot be used on the tax returns in the current year but can be carried forward to reduce taxable income or income taxes payable in a future year, for which there must be sufficient tax-basis income to utilize a portion or all of the carryforward amount to realize the deferred tax asset. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of the tax effects as of the balance sheet date of the amount of the estimated future tax deductions arising from all employee compensation and benefits costs, which can only be deducted for tax purposes when the actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from forms of compensation and benefit costs not otherwise specified in the taxonomy, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from other provisions, reserves, allowances, and liabilities, which are not otherwise reflected in deferred taxes in the taxonomy, which can only be deducted for tax purposes when relevant losses are realized or actual obligations are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from currently nondeductible expenses in accrued liabilities, which can only be deducted for tax purposes when such items are actually incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of the portions of deferred tax assets as of the balance sheet date for which, based on the weight of available evidence, it is more likely than not will not be realized through future reductions of tax-based income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cumulative amount of all deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A taxable temporary difference is a difference between the tax basis and the carrying amount of an asset or liability in the financial statements prepared in accordance with generally accepted accounting principles that will result in taxable amounts in one or more future periods. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The cumulative amount of the estimated future tax effects attributable to the difference between the tax basis of goodwill and intangible assets and the basis of goodwill and intangible assets computed in accordance with generally accepted accounting principles. The difference in basis, whether due to amortization or other reasons, will increase future taxable income when such difference reverses. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The cumulative amount of the estimated future tax effects attributable to other temporary differences not otherwise specified in this taxonomy that were expensed for tax purposes but capitalized in conformity with generally accepted accounting principles, or which were recognized as revenue under GAAP but not for tax purposes, which will reverse in future periods. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount as of the balance sheet date of the estimated future tax effects attributable to the difference between the tax basis of other long-lived assets and the basis of long-lived assets computed in accordance with generally accepted accounting principles. The basis difference, whether due to impairment charges or other reasons, will increase future taxable income when it reverses. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount as of the balance sheet date of the estimated future tax effects attributable to the difference between the tax basis of capital assets and the basis of capital assets computed in accordance with generally accepted accounting principles. The difference in basis, attributable to different capitalization of costs, depreciation, or amortization methodologies, will increase future taxable income when such basis difference is realized. Capital assets include but are not limited to assets such as land, real estate, leasehold improvements, machinery and equipment and furniture and fixtures. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Expected Expiry Dates of NOL's (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
|---|---|
|
Federal | Central Laboratory
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | $ 4,938 |
|
Federal | Central Laboratory | Expiring 2012-2014
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 226 |
|
Federal | Central Laboratory | Expiring 2015-2019
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 678 |
|
Federal | Central Laboratory | Expiring 2020-2031
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 4,034 |
|
Federal | Oxford Outcomes Limited
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 826 |
|
Federal | Oxford Outcomes Limited | Expiring 2020-2031
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 337 |
|
Federal | Oxford Outcomes Limited | Expiring 2032
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 489 |
|
State | Central Laboratory
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 13,084 |
|
State | Central Laboratory | Expiring 2012-2014
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 226 |
|
State | Central Laboratory | Expiring 2015-2019
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 678 |
|
State | Central Laboratory | Expiring 2020-2031
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 12,180 |
|
State | Clinical Research
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 1,235 |
|
State | Clinical Research | Expiring 2020-2031
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 1,235 |
|
State | Oxford Outcomes Limited
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 903 |
|
State | Oxford Outcomes Limited | Expiring 2020-2031
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | 406 |
|
State | Oxford Outcomes Limited | Expiring 2032
|
|
| Operating Loss Carryforwards [Line Items] | |
| Net operating loss carryforward | $ 497 |
| X | ||||||||||
|
- Definition
The amount of operating loss carryforwards available to reduce future taxable income, which are subject to expiration dates. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Reconciliation of Beginning and Ending Amount of Total Unrecognized Tax Benefits (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Income Tax Contingency [Line Items] | |||
| Gross amount of unrecognized tax benefits at start of year | $ 8,566 | $ 15,855 | $ 13,643 |
| Increase related to prior year tax positions | 304 | 189 | 373 |
| Decrease related to prior year tax positions | (36) | (3,861) | |
| Increase related to current year tax positions | 482 | 2,512 | |
| Settlements | (289) | (75) | |
| Lapse of statute of limitations | (2,773) | (3,328) | (598) |
| Gross amount of unrecognized tax benefits at end of year | $ 6,543 | $ 8,566 | $ 15,855 |
| X | ||||||||||
|
- Definition
Unrecognized Tax Benefits, Gross No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The gross amount of decreases in unrecognized tax benefits resulting from tax positions taken in prior period tax returns, excluding amounts pertaining to examined tax returns. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The gross amount of decreases in unrecognized tax benefits resulting from settlements with taxing authorities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The gross amount of increases in unrecognized tax benefits resulting from tax positions that have been or will be taken in the tax return for the current period, excluding amounts pertaining to examined tax returns. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The gross amount of increases in unrecognized tax benefits resulting from tax positions taken in prior period tax returns, excluding amounts pertaining to examined tax returns. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The gross amount of decreases in unrecognized tax benefits resulting from lapses of the applicable statutes of limitations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Recognized Non-Recurring Charges, Net (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2009
|
|
| Restructuring Cost and Reserve [Line Items] | ||
| Restructuring charges | $ 9,817 | $ 13,301 |
| Research and development incentives | (4,493) | |
| Net charge | $ 9,817 | $ 8,808 |
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations net of research and development incentives. No definition available.
|
| X | ||||||||||
|
- Definition
The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Non-Recurring Charges, Net - Additional Information (Detail) (USD $)
|
12 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2009
|
Mar. 31, 2011
Q1 Restructuring Plan
|
Mar. 31, 2011
Q1 Restructuring Plan
Clinical Research
|
Mar. 31, 2011
Q1 Restructuring Plan
Central Laboratory
|
Sep. 30, 2011
Q3 Restructuring Plan
Clinical Research
|
Dec. 31, 2009
Restructuring - Fiscal 2009 Plan
|
Dec. 31, 2009
Restructuring - Fiscal 2009 Plan
Clinical Research
|
Dec. 31, 2009
Restructuring - Fiscal 2009 Plan
Central Laboratory
|
Dec. 31, 2009
Restructuring - Fiscal 2009 Plan
Office Consolidations
|
Dec. 31, 2009
Restructuring - Fiscal 2009 Plan
Workforce Reduction
|
|
| Restructuring Cost and Reserve [Line Items] | |||||||||||
| Lease termination and exit costs | $ 1,000,000 | $ 900,000 | |||||||||
| Workforce reductions | 4,000,000 | 3,900,000 | |||||||||
| Restructuring charges | 9,817,000 | 13,301,000 | 5,000,000 | 3,500,000 | 1,500,000 | 4,800,000 | 13,400,000 | 12,900,000 | 500,000 | 8,500,000 | 4,900,000 |
| Research and development incentives | $ 4,493,000 | ||||||||||
| X | ||||||||||
|
- Definition
Gain (Loss) On Contract Termination And Business Exit Costs No definition available.
|
| X | ||||||||||
|
- Definition
The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The charge against earnings in the period for known and estimated costs of termination benefits provided to current employees that are involuntarily terminated under a benefit arrangement associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination or a discontinued operation as defined by generally accepted accounting principles and costs associated with one-time termination benefits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Details of Movement in Restructuring Provisions Recognised (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | 36 Months Ended | 12 Months Ended | 36 Months Ended | 12 Months Ended | 36 Months Ended |
|---|---|---|---|---|---|---|
|
Dec. 31, 2011
Restructuring - Fiscal 2011 Plan
|
Dec. 31, 2011
Restructuring - Fiscal 2009 Plan
|
Dec. 31, 2011
Workforce Reduction
Restructuring - Fiscal 2011 Plan
|
Dec. 31, 2011
Workforce Reduction
Restructuring - Fiscal 2009 Plan
|
Dec. 31, 2011
Office Consolidations
Restructuring - Fiscal 2011 Plan
|
Dec. 31, 2011
Office Consolidations
Restructuring - Fiscal 2009 Plan
|
|
| Restructuring Cost and Reserve [Line Items] | ||||||
| Initial provision recognised | $ 9,817 | $ 13,434 | $ 7,836 | $ 4,886 | $ 1,981 | $ 8,548 |
| Amounts released | (133) | (133) | ||||
| Net provision recognised | 13,301 | 4,886 | 8,415 | |||
| Cash payments | (5,689) | (11,389) | (5,438) | (4,886) | (251) | (6,503) |
| Property, plant and equipment write-off | (55) | (1,912) | (55) | (1,912) | ||
| Foreign exchange movement | (199) | (164) | (35) | |||
| Closing provision | $ 3,874 | $ 2,234 | $ 1,640 |
| X | ||||||||||
|
- Definition
Restructuring Charges Related to Asset Write Offs and Closed Facilities No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of any reversal and other adjustment made during the period to the amount of a previously accrued liability for a specified type of restructuring cost, excluding adjustments for costs incurred during the period, costs settled during the period, and foreign currency translation adjustments. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Reserve increase representing the amount charged against earnings in the period for a specified incurred and estimated type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of cash paid in the period to fully or partially settle a specified, previously accrued type of restructuring cost. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of foreign currency translation adjustment increasing or decreasing the accrual for a specified type of restructuring cost. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Provision for Doubtful Debts (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
|
| Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
| Opening provision | $ 3,284 | $ 5,210 |
| Amounts used during the year | (945) | (2,192) |
| Amounts provided during the year | 4,190 | 3,414 |
| Amounts released during the year | (1,003) | (3,148) |
| Closing provision | $ 5,526 | $ 3,284 |
| X | ||||||||||
|
- Definition
Allowance for doubtful accounts amounts released during the year. No definition available.
|
| X | ||||||||||
|
- Definition
Allowance for Doubtful Accounts, Provisions No definition available.
|
| X | ||||||||||
|
- Definition
Allowance for Doubtful Accounts amounts used during the year. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Commitments and Contingencies - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified |
12 Months Ended | 1 Months Ended | ||||
|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
Oct. 27, 2011
Maximum
|
Nov. 22, 2011
Plan 1
|
Nov. 22, 2011
Plan 2
|
|
| Operating Leased Assets [Line Items] | ||||||
| Non-cancelable operating leases for facilities expiration period | 10 years | |||||
| Operating leases rental expense | $ 52.2 | $ 46.0 | $ 45.2 | |||
| Share repurchase program | 50 | 10 | 10 | |||
| Share repurchase plan Start Date | Nov. 23, 2011 | Jan. 01, 2012 | ||||
| Share repurchase plan End Date | Dec. 31, 2011 | Feb. 20, 2012 | ||||
| Outstanding Amount under repurchase plans | $ 10.0 | |||||
| X | ||||||||||
|
- Definition
Lease Expiration Period No definition available.
|
| X | ||||||||||
|
- Definition
Share Repurchase Program, Repurchase Period End Date No definition available.
|
| X | ||||||||||
|
- Definition
Share Repurchase Program, Repurchase Period Start Date No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount authorized by an entity's Board of Directors under a stock repurchase plan. No definition available.
|
| X | ||||||||||
|
- Definition
The remaining repurchase amount authorized by an entity's Board of Directors under a stock repurchase plan. No definition available.
|
|
Future Minimum Rental Commitments for Operating Leases (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
|---|---|
| Operating Leased Assets [Line Items] | |
| 2012 | $ 36,927 |
| 2013 | 31,564 |
| 2014 | 26,582 |
| 2015 | 20,088 |
| 2016 | 16,681 |
| Thereafter | 26,884 |
| Total | $ 158,726 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The total of future contractually required payments on leases defined as operating. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due within one year of the balance sheet date relating to leases defined as operating. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due within the fifth year of the balance sheet date relating to leases defined as operating. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due within the fourth year of the balance sheet date relating to leases defined as operating. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due within the third year of the balance sheet date relating to leases defined as operating. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due within the second year of the balance sheet date relating to leases defined as operating. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
For leases having an initial or remaining non-cancelable letter-terms in excess of one year, required rental payments due after the fifth year from the balance sheet date on leases defined as operating. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Distribution of Net Revenue by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Segment Reporting Information [Line Items] | |||
| Net Revenue | $ 945,729 | $ 900,044 | $ 887,612 |
|
Ireland
|
|||
| Segment Reporting Information [Line Items] | |||
| Net Revenue | 88,869 | 128,790 | 151,618 |
|
Rest Of Europe
|
|||
| Segment Reporting Information [Line Items] | |||
| Net Revenue | 348,492 | 292,567 | 251,104 |
|
U.S.
|
|||
| Segment Reporting Information [Line Items] | |||
| Net Revenue | 393,957 | 381,196 | 408,561 |
|
Other
|
|||
| Segment Reporting Information [Line Items] | |||
| Net Revenue | $ 114,411 | $ 97,491 | $ 76,329 |
| X | ||||||||||
|
- Definition
Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Net Revenue by Business Segment (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Segment Reporting Information [Line Items] | |||
| Net Revenue | $ 945,729 | $ 900,044 | $ 887,612 |
|
Central Laboratory
|
|||
| Segment Reporting Information [Line Items] | |||
| Net Revenue | 71,549 | 63,813 | 70,656 |
|
Clinical Research
|
|||
| Segment Reporting Information [Line Items] | |||
| Net Revenue | $ 874,180 | $ 836,231 | $ 816,956 |
| X | ||||||||||
|
- Definition
Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Income from Operations by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Segment Reporting Information [Line Items] | |||
| Excluding Non- recurring charges, net | $ 39,260 | $ 92,095 | $ 116,260 |
| Non- recurring charges, net | (9,817) | (8,808) | |
| Income from operations | 29,443 | 92,095 | 107,452 |
|
Ireland
|
|||
| Segment Reporting Information [Line Items] | |||
| Excluding Non- recurring charges, net | (33,139) | 36,636 | 54,010 |
| Non- recurring charges, net | (1,564) | 73 | |
| Income from operations | (34,703) | 36,636 | 54,083 |
|
Rest Of Europe
|
|||
| Segment Reporting Information [Line Items] | |||
| Excluding Non- recurring charges, net | 35,175 | 24,212 | 21,537 |
| Non- recurring charges, net | (3,000) | 2,408 | |
| Income from operations | 32,175 | 24,212 | 23,945 |
|
U.S.
|
|||
| Segment Reporting Information [Line Items] | |||
| Excluding Non- recurring charges, net | 30,127 | 25,017 | 36,280 |
| Non- recurring charges, net | (5,253) | (11,289) | |
| Income from operations | 24,874 | 25,017 | 24,991 |
|
Other
|
|||
| Segment Reporting Information [Line Items] | |||
| Excluding Non- recurring charges, net | 7,097 | 6,230 | 4,433 |
| Income from operations | $ 7,097 | $ 6,230 | $ 4,433 |
| X | ||||||||||
|
- Definition
Operating Income Loss Before Restructuring Charges No definition available.
|
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations net of research and development incentives. No definition available.
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Details
|
|
Distribution of Income from Operations by Segment (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Excluding Non- recurring charges, net | $ 39,260 | $ 92,095 | $ 116,260 |
| Non- recurring charges, net | (9,817) | (8,808) | |
| Income from operations | 29,443 | 92,095 | 107,452 |
|
Central Laboratory
|
|||
| Excluding Non- recurring charges, net | (661) | (12,759) | 5,338 |
| Non- recurring charges, net | (1,545) | (309) | |
| Income from operations | (2,206) | (12,759) | 5,029 |
|
Clinical Research
|
|||
| Excluding Non- recurring charges, net | 39,921 | 104,854 | 110,922 |
| Non- recurring charges, net | (8,272) | (8,499) | |
| Income from operations | $ 31,649 | $ 104,854 | $ 102,423 |
| X | ||||||||||
|
- Definition
Operating Income Loss Before Restructuring Charges No definition available.
|
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations net of research and development incentives. No definition available.
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
|
Distribution of Property, Plant and Equipment, Net, by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 168,461 | $ 170,861 |
|
Ireland
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 109,953 | 109,919 |
|
Rest Of Europe
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 16,419 | 16,675 |
|
U.S.
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 33,086 | 33,855 |
|
Other
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 9,003 | $ 10,412 |
| X | ||||||||||
|
- Definition
Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Property, Plant and Equipment, Net, by Business Segment (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 168,461 | $ 170,861 |
|
Central Laboratory
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | 18,292 | 21,106 |
|
Clinical Research
|
||
| Segment Reporting Information [Line Items] | ||
| Property, plant and equipment, net | $ 150,169 | $ 149,755 |
| X | ||||||||||
|
- Definition
Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Depreciation and Amortization by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Segment Reporting Information [Line Items] | |||
| Depreciation and amortization | $ 38,682 | $ 33,873 | $ 32,659 |
|
Ireland
|
|||
| Segment Reporting Information [Line Items] | |||
| Depreciation and amortization | 15,192 | 11,840 | 9,459 |
|
Rest Of Europe
|
|||
| Segment Reporting Information [Line Items] | |||
| Depreciation and amortization | 7,057 | 5,543 | 5,960 |
|
U.S.
|
|||
| Segment Reporting Information [Line Items] | |||
| Depreciation and amortization | 12,427 | 12,422 | 13,945 |
|
Other
|
|||
| Segment Reporting Information [Line Items] | |||
| Depreciation and amortization | $ 4,006 | $ 4,068 | $ 3,295 |
| X | ||||||||||
|
- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Depreciation and Amortization by Business Segment (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Segment Reporting Information [Line Items] | |||
| Depreciation and amortization | $ 38,682 | $ 33,873 | $ 32,659 |
|
Central Laboratory
|
|||
| Segment Reporting Information [Line Items] | |||
| Depreciation and amortization | 3,721 | 4,888 | 3,724 |
|
Clinical Research
|
|||
| Segment Reporting Information [Line Items] | |||
| Depreciation and amortization | $ 34,961 | $ 28,985 | $ 28,935 |
| X | ||||||||||
|
- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Total Assets by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Assets | $ 1,035,467 | $ 949,538 |
|
Ireland
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 414,510 | 418,098 |
|
Rest Of Europe
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 216,313 | 173,668 |
|
U.S.
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 363,527 | 329,971 |
|
Other
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | $ 41,117 | $ 27,801 |
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Total Assets by Business Segment (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
|---|---|---|
| Segment Reporting Information [Line Items] | ||
| Assets | $ 1,035,467 | $ 949,538 |
|
Central Laboratory
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | 55,184 | 60,004 |
|
Clinical Research
|
||
| Segment Reporting Information [Line Items] | ||
| Assets | $ 980,283 | $ 889,534 |
| X | ||||||||||
|
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Capital Expenditures by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Property, Plant and Equipment [Line Items] | |||
| Capital Expenditures | $ 36,005 | $ 31,593 | $ 34,814 |
|
Ireland
|
|||
| Property, Plant and Equipment [Line Items] | |||
| Capital Expenditures | 16,987 | 16,095 | 11,988 |
|
Rest Of Europe
|
|||
| Property, Plant and Equipment [Line Items] | |||
| Capital Expenditures | 4,795 | 5,869 | 3,444 |
|
U.S.
|
|||
| Property, Plant and Equipment [Line Items] | |||
| Capital Expenditures | 10,222 | 5,852 | 14,730 |
|
Other
|
|||
| Property, Plant and Equipment [Line Items] | |||
| Capital Expenditures | $ 4,001 | $ 3,777 | $ 4,652 |
| X | ||||||||||
|
- Definition
The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Capital Expenditures by Business Segment (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Segment Reporting Disclosure [Line Items] | |||
| Capital Expenditure | $ 36,005 | $ 31,593 | $ 34,814 |
|
Central Laboratory
|
|||
| Segment Reporting Disclosure [Line Items] | |||
| Capital Expenditure | 1,449 | 3,991 | 10,774 |
|
Clinical Research
|
|||
| Segment Reporting Disclosure [Line Items] | |||
| Capital Expenditure | $ 34,556 | $ 27,602 | $ 24,040 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Clients Representing Company's Net Revenue (Detail)
|
12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|||||
| Revenue, Major Customer [Line Items] | |||||||
| Client A | 13.00% | [1] | [1] | ||||
|
|||||||
| X | ||||||||||
|
- Definition
Percentage of Company Revenue No definition available.
|
| X | ||||||||||
|
- Details
|
|
Distribution of Interest Income by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Segment Reporting Disclosure [Line Items] | |||
| Interest Income | $ 1,194 | $ 1,761 | $ 752 |
|
Ireland
|
|||
| Segment Reporting Disclosure [Line Items] | |||
| Interest Income | 762 | 1,277 | 175 |
|
Rest Of Europe
|
|||
| Segment Reporting Disclosure [Line Items] | |||
| Interest Income | 364 | 406 | 422 |
|
U.S.
|
|||
| Segment Reporting Disclosure [Line Items] | |||
| Interest Income | 18 | 22 | 135 |
|
Other
|
|||
| Segment Reporting Disclosure [Line Items] | |||
| Interest Income | $ 50 | $ 56 | $ 20 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Distribution of Interest Income by Business Segment (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Segment Reporting, Revenue Reconciling Item [Line Items] | |||
| Interest Income | $ 1,194 | $ 1,761 | $ 752 |
|
Central Laboratory
|
|||
| Segment Reporting, Revenue Reconciling Item [Line Items] | |||
| Interest Income | 18 | 20 | 18 |
|
Clinical Research
|
|||
| Segment Reporting, Revenue Reconciling Item [Line Items] | |||
| Interest Income | $ 1,176 | $ 1,741 | $ 734 |
| X | ||||||||||
|
- Definition
Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Distribution of Tax Charge by Geographical Area (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Income Taxes [Line Items] | |||
| Tax Charge | $ 6,115 | $ 5,653 | $ 10,375 |
|
Ireland
|
|||
| Income Taxes [Line Items] | |||
| Tax Charge | (3,475) | 5,310 | (4,544) |
|
Rest Of Europe
|
|||
| Income Taxes [Line Items] | |||
| Tax Charge | 657 | (1,606) | 4,202 |
|
U.S.
|
|||
| Income Taxes [Line Items] | |||
| Tax Charge | 4,656 | (593) | 7,820 |
|
Other
|
|||
| Income Taxes [Line Items] | |||
| Tax Charge | $ 4,277 | $ 2,542 | $ 2,897 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Distribution of Tax Charge by Business Segment (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
| Income Taxes [Line Items] | |||
| Tax Charge | $ 6,115 | $ 5,653 | $ 10,375 |
|
Central Laboratory
|
|||
| Income Taxes [Line Items] | |||
| Tax Charge | (175) | (2,858) | 610 |
|
Clinical Research
|
|||
| Income Taxes [Line Items] | |||
| Tax Charge | $ 6,290 | $ 8,511 | $ 9,765 |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Supplemental Disclosure of Cash Flow Information (Detail) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | |||||
|---|---|---|---|---|---|---|
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
||||
| Schedule of Cash Flow, Supplemental [Line Items] | ||||||
| Non-cash interest on acquisition consideration payable | $ 743 | [1] | ||||
| Cash paid for interest | 388 | 833 | 3,642 | |||
| Cash paid for income taxes | $ 22,723 | $ 14,634 | $ 12,977 | |||
|
||||||
| X | ||||||||||
|
- Definition
Non Cash Interest Expense No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash paid for interest during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Accumulated Other Comprehensive Income (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|---|---|---|---|
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
| Currency translation adjustments | $ 7,609 | $ 18,956 | |
| Currency impact on long term funding | (20,913) | (20,111) | |
| Tax on currency impact on long term funding | 1,540 | 1,246 | |
| Actuarial gain on defined benefit pension plan (note 9) | (4,060) | 305 | 1,514 |
| Unrealised capital gain(loss) - investments (note 3) | (622) | ||
| Total | $ (16,446) | $ 396 |
| X | ||||||||||
|
- Definition
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Currency Impact on Long Term Funding , Effect Pretax No definition available.
|
| X | ||||||||||
|
- Definition
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Currency Impact on Long Term Funding, Tax No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Accumulated Other Comprehensive Income (Loss), Other Net Unrealized Gains Losses On Securities No definition available.
|
| X | ||||||||||
|
- Definition
The total of net gain (loss), prior service cost (credit), and transition assets (obligations), as well as minimum pension liability if still remaining, included in accumulated other comprehensive income associated with a defined benefit pension or other postretirement plan(s) because they have yet to be recognized as components of net periodic benefit cost. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Related Parties - Additional Information (Detail)
|
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2011
EUR (€)
|
|
| Related Party Transaction [Line Items] | ||
| Related Party Transaction Amounts | $ 348,968 | € 262,500 |
| Term of Agreement with Rotrua Limited | 3 years | 3 years |
| X | ||||||||||
|
- Definition
Amount of transactions with related party during the financial reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Description of the terms and manner of settlement of the related party transaction. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
|
Subsequent Events - Additional Information (Detail) (Acquisition, USD $)
In Millions, unless otherwise specified |
Feb. 15, 2012
BeijingWits Medical Limited
|
Feb. 15, 2012
BeijingWits Medical Limited
Maximum
|
Feb. 28, 2012
PriceSpective LLC
|
Feb. 28, 2012
PriceSpective LLC
Maximum
|
|---|---|---|---|---|
| Subsequent Event [Line Items] | ||||
| Equity Method Investment Ownership Percentage | 100.00% | 100.00% | ||
| Equity method Investments | $ 9.0 | $ 40.0 | ||
| Potential additional consideration | $ 7.0 | $ 15.0 |
| X | ||||||||||
|
- Definition
Amount of potential cash payments that could result from the contingent consideration arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of cash paid to acquire the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
|
Provisional Estimates of Fair Values of Assets Acquired and Liabilities Assumed (Detail) (Acquisition, USD $)
In Thousands, unless otherwise specified |
Feb. 15, 2012
BeijingWits Medical Limited
|
Feb. 28, 2012
PriceSpective LLC
|
|---|---|---|
| Subsequent Event [Line Items] | ||
| Property, plant and equipment | $ 172 | $ 247 |
| Cash and cash equivalents | 587 | 876 |
| Accounts receivable | 657 | 6,049 |
| Other current assets | 490 | 372 |
| Current liabilities | (1,046) | (5,619) |
| Purchase price | $ 860 | $ 1,925 |
| X | ||||||||||
|
- Definition
Business Acquisition, Purchase Price Allocation, Other Current Assets No definition available.
|
| X | ||||||||||
|
- Definition
The total purchase price of the acquired entity. This includes cash paid to equity interest holders of the acquired entity, fair value of debt and equity securities issued to equity holders of the acquired entity, and transaction costs paid to third parties to consummate the acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of cash and cash equivalents acquired in a business combination. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to receivables. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to current liabilities of the acquired entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of acquisition cost of a business combination allocated to property, plant and equipment to be used in ongoing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|